

# Roxana Mehran

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/12000642/roxana-mehran-publications-by-year.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

617  
papers

61,521  
citations

107  
h-index

239  
g-index

645  
ext. papers

73,365  
ext. citations

7.2  
avg, IF

7.1  
L-index

#	Paper	IF	Citations
617	Ticagrelor Monotherapy After PCI in High-Risk Patients With Prior MI: A Prespecified TWILIGHT Substudy.. <i>JACC: Cardiovascular Interventions</i> , <b>2022</b> , 15, 282-282	5	0
616	Antithrombotic Therapy in Patients With Atrial Fibrillation After Acute Coronary Syndromes or Percutaneous Intervention.. <i>Journal of the American College of Cardiology</i> , <b>2022</b> , 79, 417-427	15.1	2
615	Short Duration of DAPT Versus De-Escalation After Percutaneous Coronary Intervention for Acute Coronary Syndromes.. <i>JACC: Cardiovascular Interventions</i> , <b>2022</b> , 15, 268-277	5	9
614	White blood cell count and clinical outcomes after left main coronary artery revascularization: insights from the EXCEL trial. <i>Coronary Artery Disease</i> , <b>2022</b> , 31, 45-51	1.4	
613	Left Ventricular Thrombus Following Acute Myocardial Infarction: JACC State-of-the-Art Review.. <i>Journal of the American College of Cardiology</i> , <b>2022</b> , 79, 1010-1022	15.1	2
612	Device and Procedure Relatedness: Viewpoint From Members of the ARC Steering Group.. <i>JACC: Cardiovascular Interventions</i> , <b>2022</b> , 15, 783-788	5	
611	Sex-Specific Considerations in the Presentation, Diagnosis, and Management of Ischemic Heart Disease: JACC Focus Seminar 2/7.. <i>Journal of the American College of Cardiology</i> , <b>2022</b> , 79, 1398-1406	15.1	0
610	Long-Term Clinical Impact of Contrast-Associated Acute Kidney Injury Following PCI: An ADAPT-DES Substudy.. <i>JACC: Cardiovascular Interventions</i> , <b>2022</b> ,	5	3
609	Dual Antiplatelet Therapy Discontinuation, Platelet Reactivity, and Adverse Outcomes After Successful Percutaneous Coronary Intervention.. <i>JACC: Cardiovascular Interventions</i> , <b>2022</b> , 15, 797-806	5	0
608	Ticagrelor With or Without Aspirin in Chinese Patients Undergoing Percutaneous Coronary Intervention: A TWILIGHT China Substudy.. <i>Circulation: Cardiovascular Interventions</i> , <b>2022</b> , CIRCINTERVENTIONS12000949	6	0
607	Balance of Ischemia and Bleeding in Selecting Intensity and Duration of Antithrombotic Regimens <b>2022</b> , 465-474		
606	Oral Antiplatelet Agents in Percutaneous Coronary Intervention <b>2022</b> , 420-438		
605	Triple Antiplatelet Therapy and Combinations with Oral Anticoagulants after Percutaneous Coronary Intervention <b>2022</b> , 453-464		
604	2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. <i>Circulation</i> , <b>2021</b> , CIR0000000000001038	16.7	23
603	Clinical Events Classification (CEC) in Clinical Trials: Report on the Current Landscape and Future Directions - Proceedings from the CEC Summit 2018.. <i>American Heart Journal</i> , <b>2021</b> , 246, 93-93	4.9	1
602	Definitions and Clinical Trial Design Principles for Coronary Artery Chronic Total Occlusion Therapies: CTO-ARC Consensus Recommendations. <i>Circulation</i> , <b>2021</b> , 143, 479-500	16.7	34
601	Risk-Benefit of 1-Year DAPT After DES Implantation in Patients Stratified by Bleeding and Ischemic Risk. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 78, 1968-1986	15.1	0

600	Duration of Dual Antiplatelet Therapy for Patients at High Bleeding Risk Undergoing PCI. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 78, 2060-2072	15.1	2
599	Prevalence and Impact of High Bleeding Risk in Patients Undergoing Left Main Artery Disease PCI. <i>JACC: Cardiovascular Interventions</i> , <b>2021</b> , 14, 2447-2457	5	1
598	2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.. <i>Journal of the American College of Cardiology</i> , <b>2021</b> ,	15.1	42
597	2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 79, 197-197	15.1	12
596	Bridging Antiplatelet Therapy After Percutaneous Coronary Intervention: JACC Review Topic of the Week. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 78, 1550-1563	15.1	2
595	Evolution of antithrombotic therapy in patients undergoing percutaneous coronary intervention: a 40-year journey. <i>European Heart Journal</i> , <b>2021</b> , 42, 339-351	9.5	24
594	Comparative influence of bleeding and ischemic risk factors on diabetic patients undergoing percutaneous coronary intervention with everolimus-eluting stents. <i>Catheterization and Cardiovascular Interventions</i> , <b>2021</b> , 98, 1111-1119	2.7	1
593	Impact of renal function in high bleeding risk patients undergoing percutaneous coronary intervention: a patient-level stratified analysis from four post-approval studies. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2021</b> , 52, 419-428	5.1	0
592	Apixaban or Vitamin K Antagonists and Aspirin or Placebo According to Kidney Function in Patients With Atrial Fibrillation After Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial. <i>Circulation</i> , <b>2021</b> , 143, 1215-1223	16.7	1
591	Incidence, predictors, and outcomes associated with acute kidney injury in patients undergoing transcatheter aortic valve replacement: from the BRAVO-3 randomized trial. <i>Clinical Research in Cardiology</i> , <b>2021</b> , 110, 649-657	6.1	2
590	Assessing the Risks of Bleeding vs Thrombotic Events in Patients at High Bleeding Risk After Coronary Stent Implantation: The ARC-High Bleeding Risk Trade-off Model. <i>JAMA Cardiology</i> , <b>2021</b> , 6, 410-419	16.2	13
589	Valve Academic Research Consortium 3: updated endpoint definitions for aortic valve clinical research. <i>European Heart Journal</i> , <b>2021</b> , 42, 1825-1857	9.5	48
588	Prognostically relevant periprocedural myocardial injury and infarction associated with percutaneous coronary interventions: a Consensus Document of the ESC Working Group on Cellular Biology of the Heart and European Association of Percutaneous Cardiovascular Interventions (EAPCI). <i>European Heart Journal</i> , <b>2021</b> , 42, 2630-2642	9.5	13
587	Impact of Percutaneous Coronary Intervention on Outcomes in Patients With Heart Failure: JACC State-of-the-Art Review. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 77, 2432-2447	15.1	5
586	Antithrombotic therapy after percutaneous coronary intervention of bifurcation lesions. <i>EuroIntervention</i> , <b>2021</b> , 17, 59-66	3.1	6
585	Impact of anemia on short-term outcomes after TAVR: A subgroup analysis from the BRAVO-3 randomized trial. <i>Catheterization and Cardiovascular Interventions</i> , <b>2021</b> , 98, E870-E880	2.7	0
584	P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials. <i>BMJ, The</i> , <b>2021</b> , 373, n1332	5.9	54
583	Incidence, predictors and clinical impact of permanent pacemaker insertion in women following transcatheter aortic valve implantation: Insights from a prospective multinational registry. <i>Catheterization and Cardiovascular Interventions</i> , <b>2021</b> , 98, E908-E917	2.7	2

582	Drug-coated stents versus bare metal stents in Academic Research Consortium-defined high bleeding risk patients. <i>EuroIntervention</i> , <b>2021</b> , 17, 240-247	3.1	1
581	Valve Academic Research Consortium 3: Updated Endpoint Definitions for Aortic Valve Clinical Research. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 77, 2717-2746	15.1	39
580	Meta-Analysis of Anticoagulation Therapy for the Prevention of Cardiovascular Events in Patients With Peripheral Arterial Disease. <i>American Journal of Cardiology</i> , <b>2021</b> , 148, 165-171	3	
579	Sex-Based Differences in Bleeding Risk After Percutaneous Coronary Intervention and Implications for the Academic Research Consortium High Bleeding Risk Criteria. <i>Journal of the American Heart Association</i> , <b>2021</b> , 10, e021965	6	9
578	Safety and efficacy of the bioabsorbable polymer everolimus-eluting stent versus durable polymer drug-eluting stents in high-risk patients undergoing PCI: TWILIGHT-SYNERGY. <i>Catheterization and Cardiovascular Interventions</i> , <b>2021</b> , 97, 63-71	2.7	2
577	Sex differences in 1-year clinical outcomes after percutaneous coronary intervention with COMBO stents: From the COMBO collaboration. <i>Catheterization and Cardiovascular Interventions</i> , <b>2021</b> , 97, 797-804	2.7	2
576	Non-cardiac surgery in patients with coronary artery disease: risk evaluation and periprocedural management. <i>Nature Reviews Cardiology</i> , <b>2021</b> , 18, 37-57	14.8	9
575	Procedural and 1-year clinical outcomes of orbital atherectomy for treatment of coronary in-stent restenosis: A single-center, retrospective study. <i>Catheterization and Cardiovascular Interventions</i> , <b>2021</b> , 97, E280-E287	2.7	2
574	Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent. <i>American Heart Journal</i> , <b>2021</b> , 231, 147-156	4.9	10
573	Reducing the cost of managing patients with atrial fibrillation undergoing percutaneous coronary intervention with stenting. <i>Journal of Cardiology</i> , <b>2021</b> , 77, 93-99	3	
572	Preprocedural anemia in females undergoing transcatheter aortic valve implantation: Insights from the WIN-TAVI registry. <i>Catheterization and Cardiovascular Interventions</i> , <b>2021</b> , 97, E704-E715	2.7	3
571	2020 ACC Expert Consensus Decision Pathway for Anticoagulant and Antiplatelet Therapy in Patients With Atrial Fibrillation or Venous Thromboembolism Undergoing Percutaneous Coronary Intervention or With Atherosclerotic Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i> , <b>2021</b> , 143, e173-e283	15.1	45
570	Moving from dual antiplatelet therapy to monotherapy based on P2Y12 receptor blockade: Why it could be a novel paradigm? <b>2021</b> , 167-191		
569	Design and rationale of a randomized trial of COBRA PzF stenting to REDUCE duration of triple therapy (COBRA-REDUCE). <i>Cardiovascular Revascularization Medicine</i> , <b>2021</b> ,	1.6	2
568	Relationship between insulin resistance, coronary plaque, and clinical outcomes in patients with acute coronary syndromes: an analysis from the PROSPECT study. <i>Cardiovascular Diabetology</i> , <b>2021</b> , 20, 10	8.7	3
567	Radial versus femoral access for coronary interventions: An updated systematic review and meta-analysis of randomized trials. <i>Catheterization and Cardiovascular Interventions</i> , <b>2021</b> , 97, 1387-1396	2.7	10
566	One-Year COMBO Stent Outcomes in Acute Coronary Syndrome: from the COMBO Collaboration. <i>Cardiovascular Drugs and Therapy</i> , <b>2021</b> , 35, 309-320	3.9	0
565	Ticagrelor Monotherapy Versus Dual-Antiplatelet Therapy After PCI: An Individual Patient-Level Meta-Analysis. <i>JACC: Cardiovascular Interventions</i> , <b>2021</b> , 14, 444-456	5	3

564	Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective: 2021 Update. <i>Circulation</i> , <b>2021</b> , 143, 583-596	16.7	31
563	Stent Thrombosis Risk Over Time on the Basis of Clinical Presentation and Platelet Reactivity: Analysis From ADAPT-DES. <i>JACC: Cardiovascular Interventions</i> , <b>2021</b> , 14, 417-427	5	4
562	Impact of Age on the Safety and Efficacy of Ticagrelor Monotherapy in Patients Undergoing PCI. <i>JACC: Cardiovascular Interventions</i> , <b>2021</b> , 14, 1434-1446	5	1
561	Perioperative risk and antiplatelet management in patients undergoing non-cardiac surgery within 1 year of PCI. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2021</b> , 1	5.1	1
560	Bleeding avoidance strategies in percutaneous coronary intervention. <i>Nature Reviews Cardiology</i> , <b>2021</b> ,	14.8	10
559	Ticagrelor monotherapy in patients with chronic kidney disease undergoing percutaneous coronary intervention: TWILIGHT-CKD. <i>European Heart Journal</i> , <b>2021</b> , 42, 4683-4693	9.5	5
558	Guided and unguided de-escalation from potent P2Y12 inhibitors among patients with ACS: a meta-analysis. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , <b>2021</b> ,	6.4	3
557	Sex Differences Among Patients With High Risk Receiving Ticagrelor With or Without Aspirin After Percutaneous Coronary Intervention: A Subgroup Analysis of the TWILIGHT Randomized Clinical Trial. <i>JAMA Cardiology</i> , <b>2021</b> , 6, 1032-1041	16.2	8
556	Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , <b>2021</b> ,	6.4	14
555	3- or 1-Month DAPT in Patients at High Bleeding Risk Undergoing Everolimus-Eluting Stent Implantation. <i>JACC: Cardiovascular Interventions</i> , <b>2021</b> , 14, 1870-1883	5	14
554	Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR. <i>European Heart Journal</i> , <b>2021</b> , 42, 4624-4634	9.5	6
553	Interventions in Ischemic Heart Disease <b>2021</b> , 93-108		
552	Efficacy and Safety of Antithrombotic Therapy in Patients With Atrial Fibrillation, Recent Acute Coronary Syndrome, or Percutaneous Coronary Intervention and a History of Heart Failure: Insights From the AUGUSTUS Trial. <i>Journal of the American Heart Association</i> , <b>2021</b> , e023143	6	
551	Comparison of One-Year Outcomes in Patients >75 Versus ≤75 Years With Coronary Artery Disease Treated With COMBO Stents (From The MASCOT Registry). <i>American Journal of Cardiology</i> , <b>2020</b> , 127, 1-8	3	2
550	1-Year Outcomes with COMBO Stents in Small-Vessel Coronary Disease: Subgroup Analysis From the COMBO Collaboration. <i>Cardiovascular Revascularization Medicine</i> , <b>2020</b> , 21, 1542-1547	1.6	2
549	Sex-Based Outcomes in Patients With a High Bleeding Risk After Percutaneous Coronary Intervention and 1-Month Dual Antiplatelet Therapy: A Secondary Analysis of the LEADERS FREE Randomized Clinical Trial. <i>JAMA Cardiology</i> , <b>2020</b> , 5, 939-947	16.2	10
548	Coronary Calcification and Long-Term Outcomes According to Drug-Eluting Stent Generation. <i>JACC: Cardiovascular Interventions</i> , <b>2020</b> , 13, 1417-1428	5	20
547	Bleeding Risk, Dual Antiplatelet Therapy Cessation, and Adverse Events After Percutaneous Coronary Intervention: The PARIS Registry. <i>Circulation: Cardiovascular Interventions</i> , <b>2020</b> , 13, e008226	6	9

546	Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From AUGUSTUS. <i>Circulation</i> , <b>2020</b> , 141, 1618-1627	16.7	48
545	Impact of insulin treated and non-insulin-treated diabetes compared to patients without diabetes on 1-year outcomes following contemporary PCI. <i>Catheterization and Cardiovascular Interventions</i> , <b>2020</b> , 96, 298-308	2.7	7
544	Nonculprit Lesion Plaque Morphology in Patients With ST-Segment-Elevation Myocardial Infarction: Results From the COMPLETE Trial Optical Coherence Tomography Substudy. <i>Circulation: Cardiovascular Interventions</i> , <b>2020</b> , 13, e008768	6	24
543	Prognostic Impact of Race in Patients Undergoing PCI: Analysis From 10 Randomized Coronary Stent Trials. <i>JACC: Cardiovascular Interventions</i> , <b>2020</b> , 13, 1586-1595	5	16
542	Optimal Antithrombotic Regimens for Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: An Updated Network Meta-analysis. <i>JAMA Cardiology</i> , <b>2020</b> , 5, 582-589	16.2	34
541	Ticagrelor With or Without Aspirin After PCI: The TWILIGHT Platelet Substudy. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 75, 578-586	15.1	39
540	1-year results after PCI with the COMBO stent in all-comers in Asia versus Europe: Geographical insights from the COMBO collaboration. <i>International Journal of Cardiology</i> , <b>2020</b> , 307, 17-23	3.2	1
539	Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease. <i>Nature Reviews Cardiology</i> , <b>2020</b> , 17, 242-257	14.8	41
538	Long-Term Safety and Efficacy of Durable Polymer Cobalt-Chromium Everolimus-Eluting Stents in Patients at High Bleeding Risk: A Patient-Level Stratified Analysis From Four Postapproval Studies. <i>Circulation</i> , <b>2020</b> , 141, 891-901	16.7	16
537	1-Year Clinical Outcomes of All-Comers Treated With 2 Bioresorbable Polymer-Coated Sirolimus-Eluting Stents: Propensity Score-Matched Comparison of the COMBO and Ultrathin-Strut Orsiro Stents. <i>JACC: Cardiovascular Interventions</i> , <b>2020</b> , 13, 820-830	5	6
536	Ticagrelor With or Without Aspirin in High-Risk Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 75, 2403-2413	15.1	34
535	Ticagrelor With or Without Aspirin After Complex PCI. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 75, 2414-2424	15.1	58
534	Pharmacodynamic Effects of Vorapaxar in Prior Myocardial Infarction Patients Treated With Potent Oral P2Y Receptor Inhibitors With and Without Aspirin: Results of the VORA-PRATIC Study. <i>Journal of the American Heart Association</i> , <b>2020</b> , 9, e015865	6	9
533	Sex-Related Differences in Patients at High Bleeding Risk Undergoing Percutaneous Coronary Intervention: A Patient-Level Pooled Analysis From 4 Postapproval Studies. <i>Journal of the American Heart Association</i> , <b>2020</b> , 9, e014611	6	5
532	Abluminus DES+ for the treatment of coronary artery disease in patients with diabetes mellitus. <i>Future Cardiology</i> , <b>2020</b> , 16, 613-623	1.3	2
531	Validation of the Academic Research Consortium High Bleeding Risk Definition in Contemporary PCI Patients. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 75, 2711-2722	15.1	53
530	A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement. <i>New England Journal of Medicine</i> , <b>2020</b> , 382, 120-129	59.2	185
529	Impact of high on-treatment platelet reactivity on outcomes following PCI in patients on hemodialysis: An ADAPT-DES substudy. <i>Catheterization and Cardiovascular Interventions</i> , <b>2020</b> , 96, 793-807	2.7	5

528	Association of Sex With Outcomes in Patients Undergoing Percutaneous Coronary Intervention: A Subgroup Analysis of the GLOBAL LEADERS Randomized Clinical Trial. <i>JAMA Cardiology</i> , <b>2020</b> , 5, 21-29	16.2	23
527	Stent Thrombosis in Patients With Atrial Fibrillation Undergoing Coronary Stenting in the AUGUSTUS Trial. <i>Circulation</i> , <b>2020</b> , 141, 781-783	16.7	48
526	Comparison of Age (. <i>American Journal of Cardiology</i> , <b>2020</b> , 125, 685-693	3	1
525	Clinical outcomes after TAVR with heparin or bivalirudin as periprocedural anticoagulation in patients with and without peripheral arterial disease: Results from the BRAVO-3 randomized trial. <i>Catheterization and Cardiovascular Interventions</i> , <b>2020</b> , 96, E377-E386	2.7	3
524	Individual Patient Data Pooled Analysis of Randomized Trials of Bivalirudin versus Heparin in Acute Myocardial Infarction: Rationale and Methodology. <i>Thrombosis and Haemostasis</i> , <b>2020</b> , 120, 348-362	7	8
523	Safety and efficacy of bivalirudin monotherapy in patients with non-ST-segment elevation acute coronary syndromes with positive biomarkers undergoing percutaneous coronary intervention: a report from the Acute Catheterization and Urgent Intervention Triage Strategy trial. <i>Coronary</i>	1.4	1
522	Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS. <i>European Heart Journal</i> , <b>2020</b> , 41, 3533-3545	9.5	37
521	Standardized definitions for evaluation of heart failure therapies: scientific expert panel from the Heart Failure Collaboratory and Academic Research Consortium. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 2175-2186	12.3	8
520	2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants: A Report of the American College of Cardiology Solution Set Oversight Committee. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 76, 594-622	15.1	69
519	Standardized Definitions for Evaluation of Heart Failure Therapies: Scientific Expert Panel From the Heart Failure Collaboratory and Academic Research Consortium. <i>JACC: Heart Failure</i> , <b>2020</b> , 8, 961-972	7.9	4
518	1-Year COMBO stent outcomes stratified by the PARIS bleeding prediction score: From the MASCOT registry. <i>IJC Heart and Vasculature</i> , <b>2020</b> , 31, 100605	2.4	1
517	One-Month Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention With Zotarolimus-Eluting Stents in High-Bleeding-Risk Patients. <i>Circulation: Cardiovascular Interventions</i> , <b>2020</b> , 13, e009565	6	17
516	Safety and Efficacy of Double Antithrombotic Therapy With Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis. <i>Journal of the American Heart Association</i> , <b>2020</b> , 9, e017212	6	24
515	Nonculprit Lesion Severity and Outcome of Revascularization in Patients With STEMI and Multivessel Coronary Disease. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 76, 1277-1286	15.1	6
514	Trial Design Principles for Patients at High Bleeding Risk Undergoing PCI: JACC Scientific Expert Panel. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 76, 1468-1483	15.1	16
513	Angiographic Restenosis in Coronary Bifurcations Treatment with Regular Drug Eluting Stents and Dedicated Bifurcation Drug-Eluting BIOSS Stents: Analysis Based on Randomized POLBOS I and POLBOS II Studies. <i>Cardiovascular Therapeutics</i> , <b>2020</b> , 2020, 6760205	3.3	3
512	Relationship Between Stent Diameter, Platelet Reactivity, and Thrombotic Events After Percutaneous Coronary Artery Revascularization. <i>American Journal of Cardiology</i> , <b>2019</b> , 124, 1363-1371	3	1
511	Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial. <i>Circulation</i> , <b>2019</b> , 140, 1921-1932	16.7	40

510	Hospitalization Among Patients With Atrial Fibrillation and a Recent Acute Coronary Syndrome or Percutaneous Coronary Intervention Treated With Apixaban or Aspirin: Insights From the AUGUSTUS Trial. <i>Circulation</i> , <b>2019</b> , 140, 1960-1963	16.7	6
509	Sex Differences in Transfemoral Transcatheter Aortic Valve Replacement. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 74, 2758-2767	15.1	28
508	Ticagrelor with or without Aspirin in High-Risk Patients after PCI. <i>New England Journal of Medicine</i> , <b>2019</b> , 381, 2032-2042	59.2	395
507	Safety and efficacy of the COMBO bio-engineered stent in an all-comer PCI cohort: 1-Year final clinical outcomes from the MASCOT post-marketing registry. <i>International Journal of Cardiology</i> , <b>2019</b> , 283, 67-72	3.2	14
506	Predictors of mortality in patients with non-anterior ST-segment elevation myocardial infarction: Analysis from the HORIZONS-AMI trial. <i>Catheterization and Cardiovascular Interventions</i> , <b>2019</b> , 94, 172-180	27	7
505	Impact of calcification on percutaneous coronary intervention: MACE-Trial 1-year results. <i>Catheterization and Cardiovascular Interventions</i> , <b>2019</b> , 94, 187-194	2.7	15
504	Association of International Normalized Ratio Stability and Bleeding Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , <b>2019</b> , 12, e007124	6	8
503	Rationale and design of the Onyx ONE global randomized trial: A randomized controlled trial of high-bleeding risk patients after stent placement with 1 month of dual antiplatelet therapy. <i>American Heart Journal</i> , <b>2019</b> , 214, 134-141	4.9	24
502	Safety and Efficacy of Antithrombotic Strategies in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Network Meta-analysis of Randomized Controlled Trials. <i>JAMA Cardiology</i> , <b>2019</b> , 4, 747-755	16.2	130
501	ST-segment elevation myocardial infarction. <i>Nature Reviews Disease Primers</i> , <b>2019</b> , 5, 39	51.1	78
500	Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. <i>European Heart Journal</i> , <b>2019</b> , 40, 2632-2653	9.5	169
499	Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention. <i>Circulation</i> , <b>2019</b> , 140, 240-261	16.7	183
498	Dual-Antiplatelet Therapy Cessation and Cardiovascular Risk in Relation to Age: Analysis From the PARIS Registry. <i>JACC: Cardiovascular Interventions</i> , <b>2019</b> , 12, 983-992	5	6
497	Residual Inflammatory Risk in Patients With Low LDL Cholesterol Levels Undergoing Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 73, 2401-2409	15.1	25
496	Influence of Baseline Anemia on Dual Antiplatelet Therapy Cessation and Risk of Adverse Events After Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , <b>2019</b> , 12, e007133	6	10
495	Impact of Race and Ethnicity on the Clinical and Angiographic Characteristics, Social Determinants of Health, and 1-Year Outcomes After Everolimus-Eluting Coronary Stent Procedures in Women. <i>Circulation: Cardiovascular Interventions</i> , <b>2019</b> , 12, e006918	6	5
494	Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation. <i>New England Journal of Medicine</i> , <b>2019</b> , 380, 1509-1524	59.2	538
493	Predictors, Incidence, and Outcomes of Patients Undergoing Transfemoral Transcatheter Aortic Valve Implantation Complicated by Stroke. <i>Circulation: Cardiovascular Interventions</i> , <b>2019</b> , 12, e007546	6	26



492	Atrial fibrillation, with ACS and PCI: walking a tightrope. <i>European Heart Journal</i> , <b>2019</b> , 40, 1563-1566	9.5	4
491	Associations between use of prasugrel vs clopidogrel and outcomes by type of acute coronary syndrome: an analysis from the PROMETHEUS registry. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2019</b> , 48, 42-51	5.1	3
490	Adverse events in patients with high platelet reactivity following successful chronic total occlusion PCI: The Assessment of Dual AntiPlatelet Therapy with Drug-Eluting Stents (ADAPT-DES) study. <i>American Heart Journal</i> , <b>2019</b> , 211, 68-76	4.9	2
489	Usefulness of Clopidogrel Loading in Patients Who Underwent Transcatheter Aortic Valve Implantation (from the BRAVO-3 Randomized Trial). <i>American Journal of Cardiology</i> , <b>2019</b> , 123, 1494-1500	3	10
488	Geographical Variations in Patterns of DAPT Cessation and Two-Year PCI Outcomes: Insights from the PARIS Registry. <i>Thrombosis and Haemostasis</i> , <b>2019</b> , 119, 1704-1711	7	2
487	Design and rationale of the COMPLETE trial: A randomized, comparative effectiveness study of complete versus culprit-only percutaneous coronary intervention to treat multivessel coronary artery disease in patients presenting with ST-segment elevation myocardial infarction. <i>American Heart Journal</i> , <b>2019</b> , 215, 157-166	4.9	11
486	Management of Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing PCI: JACC State-of-the-Art Review. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 74, 83-99	15.1	84
485	Impact of Smoking on Platelet Reactivity and Clinical Outcomes After Percutaneous Coronary Intervention: Findings From the ADAPT-DES Study. <i>Circulation: Cardiovascular Interventions</i> , <b>2019</b> , 12, e007982	6	4
484	Potential Clinical Advantages of Drug-Coated Balloon in Specific Clinical Settings <b>2019</b> , 69-79		
483	The link between anemia and adverse outcomes in patients with acute coronary syndrome. <i>Expert Review of Cardiovascular Therapy</i> , <b>2019</b> , 17, 151-159	2.5	7
482	Novel Oral Anticoagulant Based Versus Vitamin K Antagonist Based Double Therapy Among Stented Patients With Atrial Fibrillation: Insights From the PIONEER AF-PCI Trial. <i>Circulation: Cardiovascular Interventions</i> , <b>2019</b> , 12, e008160	6	0
481	Rate of peri-procedural stroke observed with cerebral embolic protection during transcatheter aortic valve replacement: a patient-level propensity-matched analysis. <i>European Heart Journal</i> , <b>2019</b> , 40, 1334-1340	9.5	52
480	Cost Implications of Anticoagulation Strategies After Percutaneous Coronary Intervention Among Patients With Atrial Fibrillation (A PIONEER-AF PCI Analysis). <i>American Journal of Cardiology</i> , <b>2019</b> , 123, 355-360	3	5
479	Tailoring Antiplatelet Therapy Intensity to Ischemic and Bleeding Risk. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2019</b> , 12, e004945	5.8	3
478	New-generation drug-eluting stents for left main coronary artery disease according to the EXCEL trial enrollment criteria: Insights from the all-comers, international, multicenter DELTA-2 registry. <i>International Journal of Cardiology</i> , <b>2019</b> , 280, 30-37	3.2	2
477	Incidence, predictors, and outcomes of DAPT disruption due to non-compliance vs. bleeding after PCI: insights from the PARIS Registry. <i>Clinical Research in Cardiology</i> , <b>2019</b> , 108, 643-650	6.1	12
476	Patterns and Impact of Dual Antiplatelet Cessation on Cardiovascular Risk After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndromes. <i>American Journal of Cardiology</i> , <b>2019</b> , 123, 709-716	3	3
475	Antithrombotic Therapy After Transcatheter Aortic Valve Replacement. <i>Circulation: Cardiovascular Interventions</i> , <b>2019</b> , 12, e007411	6	28

474	The prevalence, predictors and outcomes of guideline-directed medical therapy in patients with acute myocardial infarction undergoing PCI, an analysis from the PROMETHEUS registry. <i>Catheterization and Cardiovascular Interventions</i> , <b>2019</b> , 93, E112-E119	2.7	6
473	Impact of Point-of-Care Platelet Function Testing Among Patients With and Without Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents (from the ADAPT-DES Study). <i>American Journal of Cardiology</i> , <b>2019</b> , 123, 549-557	3	2
472	Impact of Pre-Diabetes on Coronary Plaque Composition and Clinical Outcome in Patients With Acute Coronary Syndromes: An Analysis From the PROSPECT Study. <i>JACC: Cardiovascular Imaging</i> , <b>2019</b> , 12, 733-741	8.4	8
471	Report of the European Society of Cardiology Cardiovascular Round Table regulatory workshop update of the evaluation of new agents for the treatment of acute coronary syndrome: Executive summary. <i>European Heart Journal: Acute Cardiovascular Care</i> , <b>2019</b> , 8, 745-754	4.3	1
470	2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. <i>Circulation</i> , <b>2018</b> , 137, 961-972	16.7	175
469	2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. <i>Journal of the American College of Cardiology</i> , <b>2018</b> , 71, 1021-1034	15.1	122
468	Incidence, determinants and clinical impact of definite stent thrombosis on mortality in women: From the WIN-DES collaborative patient-level pooled analysis. <i>International Journal of Cardiology</i> , <b>2018</b> , 263, 24-28	3.2	6
467	Associations Between Complex PCI and Prasugrel or Clopidogrel Use in Patients With Acute Coronary Syndrome Who Undergo PCI: From the PROMETHEUS Study. <i>Canadian Journal of Cardiology</i> , <b>2018</b> , 34, 319-329	3.8	13
466	Percutaneous coronary intervention of lesions with in-stent restenosis: A report from the ADAPT-DES study. <i>American Heart Journal</i> , <b>2018</b> , 197, 142-149	4.9	4
465	Predictors of Left Ventricular Ejection Fraction Improvement After Primary Stenting in ST-Segment Elevation Myocardial Infarction (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction Trial). <i>American Journal of Cardiology</i> , <b>2018</b> , 121, 678-683	3	9
464	Computed tomography predictors of mortality, stroke and conduction disturbances in women undergoing TAVR: A sub-analysis of the WIN-TAVI registry. <i>Journal of Cardiovascular Computed Tomography</i> , <b>2018</b> , 12, 338-343	2.8	15
463	An open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rationale and design of the AUGUSTUS trial. <i>Journal of Thrombosis and Haemostasis</i> , <b>2018</b> , 17, 222-232	4.9	56
462	Bleeding Severity After Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , <b>2018</b> , 11, e005542	6	8
461	Incidence, Patterns, and Impact of Dual Antiplatelet Therapy Cessation Among Patients With and Without Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention: Results From the PARIS Registry (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients). <i>Circulation: Cardiovascular Interventions</i> , <b>2018</b> , 11, e005541	6	15
460	Effect of Procedure and Coronary Lesion Characteristics on Clinical Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention: Insights From the PIONEER AF-PCI Trial. <i>JACC: Cardiovascular Interventions</i> , <b>2018</b> , 11, 626-634	5	19
459	Percutaneous coronary intervention of bifurcation lesions and platelet reactivity. <i>International Journal of Cardiology</i> , <b>2018</b> , 250, 92-97	3.2	4
458	Impact of percutaneous coronary intervention extent, complexity and platelet reactivity on outcomes after drug-eluting stent implantation. <i>International Journal of Cardiology</i> , <b>2018</b> , 268, 61-67	3.2	18
457	Complete Revascularization During Primary Percutaneous Coronary Intervention Reduces Death and Myocardial Infarction in Patients With Multivessel Disease: Meta-Analysis and Meta-Regression of Randomized Trials. <i>JACC: Cardiovascular Interventions</i> , <b>2018</b> , 11, 833-843	5	39

456	Dual Antiplatelet Therapy Cessation and Adverse Events After Drug-Eluting Stent Implantation in Patients at High Risk for Atherothrombosis (from the PARIS Registry). <i>American Journal of Cardiology</i> , <b>2018</b> , 122, 1638-1646	3	12
455	Impact of high on-aspirin platelet reactivity on outcomes following successful percutaneous coronary intervention with drug-eluting stents. <i>American Heart Journal</i> , <b>2018</b> , 205, 77-86	4.9	2
454	Safety and efficacy of non-vitamin K oral anticoagulant for atrial fibrillation patients after percutaneous coronary intervention: A bivariate analysis of the PIONEER AF-PCI and RE-DUAL PCI trial. <i>American Heart Journal</i> , <b>2018</b> , 203, 17-24	4.9	9
453	Standardized End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2 Consensus Document. <i>European Heart Journal</i> , <b>2018</b> , 39, 2192-2207	9.5	9 <sup>1</sup>
452	Standardized End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2 Consensus Document. <i>Circulation</i> , <b>2018</b> , 137, 2635-2650	16.7	17 <sup>2</sup>
451	Platelet Reactivity and Risk of Ischemic Stroke After Coronary Drug-Eluting Stent Implantation: From the ADAPT-DES Study. <i>JACC: Cardiovascular Interventions</i> , <b>2018</b> , 11, 1277-1286	5	7
450	Impact of bleeding assessment and adjudication methodology on event rates and clinical trial outcomes: insights from the HORIZONS-AMI trial. <i>EuroIntervention</i> , <b>2018</b> , 14, e580-e587	3.1	2
449	Bleeding Associated with Angiography and Percutaneous Coronary Intervention <b>2018</b> , 503-522		
448	Use of Bivalirudin for Anticoagulation in Interventional Cardiovascular Procedures. <i>Cardiovascular Innovations and Applications</i> , <b>2018</b> , 3, 163-174	0.1	
447	Efficacy and safety of bivalirudin in coronary artery disease patients with mild to moderate chronic kidney disease: Meta-analysis. <i>Journal of Cardiology</i> , <b>2018</b> , 71, 494-504	3	4
446	Non-vitamin K Antagonist Oral Anticoagulant After Acute Coronary Syndrome: Is There a Role?. <i>Interventional Cardiology Review</i> , <b>2018</b> , 13, 93-98	4.2	3
445	Prediction of Ischemic and Bleeding Events Using the Dual Antiplatelet Therapy Score in an Unrestricted Percutaneous Coronary Intervention Population. <i>Circulation: Cardiovascular Interventions</i> , <b>2018</b> , 11, e006853	6	9
444	Relationship Between Intravascular Ultrasound Guidance and Clinical Outcomes After Drug-Eluting Stents. <i>Circulation: Cardiovascular Interventions</i> , <b>2018</b> , 11, e006243	6	22
443	Gender differences on benefits and risks associated with oral antithrombotic medications for coronary artery disease. <i>Expert Opinion on Drug Safety</i> , <b>2018</b> , 17, 1041-1052	4.1	12
442	1-Year Clinical Outcomes of All-Coroner Patients Treated With the Dual-Therapy COMBO Stent: Primary Results of the COMBO Collaboration. <i>JACC: Cardiovascular Interventions</i> , <b>2018</b> , 11, 1969-1978	5	14
441	CSL112, a reconstituted, infusible, plasma-derived apolipoprotein A-I: safety and tolerability profiles and implications for management in patients with myocardial infarction. <i>Expert Opinion on Investigational Drugs</i> , <b>2018</b> , 27, 997-1005	5.9	13
440	Optimal Duration of Dual Antiplatelet Therapy After Left Main Coronary Stenting. <i>Journal of the American College of Cardiology</i> , <b>2018</b> , 72, 2086-2087	15.1	13
439	Determinants of Significant Out-Of-Hospital Bleeding in Patients Undergoing Percutaneous Coronary Intervention. <i>Thrombosis and Haemostasis</i> , <b>2018</b> , 118, 1997-2005	7	14

438	Total bleeding with rivaroxaban versus warfarin in patients with atrial fibrillation receiving antiplatelet therapy after percutaneous coronary intervention. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2018</b> , 46, 346-350	5.1	8
437	Japan-United States of America Harmonized Assessment by Randomized Multicentre Study of OrbusNEich Combo StEnt (Japan-USA HARMONEE) study: primary results of the pivotal registration study of combined endothelial progenitor cell capture and drug-eluting stent in patients with ischaemic coronary disease and non-ST-elevation acute coronary syndrome. <i>European Heart Journal</i> , <b>2018</b> , 39, 132-139	9.5	35
436	Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention. <i>Nature Reviews Cardiology</i> , <b>2018</b> , 15, 480-496	14.8	134
435	Is routine post-procedural anticoagulation warranted after primary percutaneous coronary intervention in ST-segment elevation myocardial infarction? Insights from the HORIZONS-AMI trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , <b>2017</b> , 6, 650-658	4.3	4
434	Angiographic predictors of 2-year stent thrombosis in patients receiving drug-eluting stents: Insights from the ADAPT-DES study. <i>Catheterization and Cardiovascular Interventions</i> , <b>2017</b> , 89, 26-35	2.7	14
433	Utility of post-procedural anticoagulation after primary PCI for STEMI: insights from a pooled analysis of the HORIZONS-AMI and EUROMAX trials. <i>European Heart Journal: Acute Cardiovascular Care</i> , <b>2017</b> , 6, 659-665	4.3	12
432	Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study. <i>American Heart Journal</i> , <b>2017</b> , 184, 81-87	4.9	78
431	Sex Differences in the Clinical Impact of High Platelet Reactivity After Percutaneous Coronary Intervention With Drug-Eluting Stents: Results From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents). <i>Circulation: Cardiovascular Interventions</i> , <b>2017</b> , 10,	6	17
430	Incidence, Predictors, and Outcomes of High-Grade Atrioventricular Block in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention (from the HORIZONS-AMI Trial). <i>American Journal of Cardiology</i> , <b>2017</b> , 119, 1295-1301	3	18
429	Effect of Short Procedural Duration With Bivalirudin on Increased Risk of Acute Stent Thrombosis in Patients With STEMI: A Secondary Analysis of the HORIZONS-AMI Randomized Clinical Trial. <i>JAMA Cardiology</i> , <b>2017</b> , 2, 673-677	16.2	4
428	Impact of pre-existing or new-onset atrial fibrillation on 30-day clinical outcomes following transcatheter aortic valve replacement: Results from the BRAVO 3 randomized trial. <i>Catheterization and Cardiovascular Interventions</i> , <b>2017</b> , 90, 1027-1037	2.7	6
427	Percutaneous Coronary Intervention of Saphenous Vein Graft. <i>Circulation: Cardiovascular Interventions</i> , <b>2017</b> , 10,	6	22
426	Patterns and associations between DAPT cessation and 2-year clinical outcomes in left main/proximal LAD versus other PCI: Results from the Patterns of Non-Adherence to Dual Antiplatelet Therapy in Stented Patients (PARIS) registry. <i>International Journal of Cardiology</i> , <b>2017</b> , 212, 132-139	3.2	8
425	Effect of valve design and anticoagulation strategy on 30-day clinical outcomes in transcatheter aortic valve replacement: Results from the BRAVO 3 randomized trial. <i>Catheterization and Cardiovascular Interventions</i> , <b>2017</b> , 90, 1016-1026	2.7	3
424	Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease. <i>New England Journal of Medicine</i> , <b>2017</b> , 377, 111-121	59.2	991
423	Comparison of Outcomes and Prognosis of Patients With Versus Without Newly Diagnosed Diabetes Mellitus After Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction (the HORIZONS-AMI Study). <i>American Journal of Cardiology</i> , <b>2017</b> , 119, 1917-1923	3	15
422	Incidence, Patterns, and Associations Between Dual-Antiplatelet Therapy Cessation and Risk for Adverse Events Among Patients With and Without Diabetes Mellitus Receiving Drug-Eluting Stents: Results From the PARIS Registry. <i>JACC: Cardiovascular Interventions</i> , <b>2017</b> , 10, 645-654	5	15
421	Platelet Reactivity and Clinical Outcomes After Coronary Artery Implantation of Drug-Eluting Stents in Subjects With Peripheral Arterial Disease: Analysis From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents). <i>Circulation: Cardiovascular Interventions</i> , <b>2017</b> , 10,	6	5

420	Relation of Baseline Hemoglobin Levels and Adverse Events in Patients With Acute Coronary Syndromes (from the Acute Catheterization and Urgent Intervention Triage strategy and Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction Trials). <i>American Journal of Cardiology</i> , <b>2017</b> , 119, 1710-1716	3	26
419	Two-year outcomes after percutaneous coronary intervention of calcified lesions with drug-eluting stents. <i>International Journal of Cardiology</i> , <b>2017</b> , 231, 61-67	3.2	45
418	Exome-wide association study of plasma lipids in >300,000 individuals. <i>Nature Genetics</i> , <b>2017</b> , 49, 1758-1766	3.6	310
417	International Expert Consensus on Switching Platelet P2Y Receptor-Inhibiting Therapies. <i>Circulation</i> , <b>2017</b> , 136, 1955-1975	16.7	215
416	Characterization of the Average Daily Ischemic and Bleeding Risk After Primary PCI for STEMI. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 70, 1846-1857	15.1	34
415	Outcomes in elderly and young patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with bivalirudin versus heparin: Pooled analysis from the EUROMAX and HORIZONS-AMI trials. <i>American Heart Journal</i> , <b>2017</b> , 194, 73-82	4.9	9
414	White Blood Cell Count and Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention in the Contemporary Era: Insights From the PARIS Study (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients Registry). <i>Circulation: Cardiovascular Interventions</i> , <b>2017</b> , 10,	6	15
413	Atrial fibrillation, bleeding, and coronary intervention: current recommendations. <i>Coronary Artery Disease</i> , <b>2017</b> , 28, 702-709	1.4	
412	Correlation of Admission Heart Rate With Angiographic and Clinical Outcomes in Patients With Right Coronary Artery ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: HORIZONS-AMI (The Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial. <i>Journal of the American Heart Association</i> , <b>2017</b> , 6,	6	8
411	Prognostic implications of Q waves at presentation in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: An analysis of the HORIZONS-AMI study. <i>Clinical Cardiology</i> , <b>2017</b> , 40, 982-987	3.3	3
410	Quantifying Ischemic Risk After Percutaneous Coronary Intervention Attributable to High Platelet Reactivity on Clopidogrel (From the Assessment of Dual Antiplatelet Therapy with Drug-Eluting Stents Study). <i>American Journal of Cardiology</i> , <b>2017</b> , 120, 917-923	3	9
409	Thrombo-embolic prevention after transcatheter aortic valve implantation. <i>European Heart Journal</i> , <b>2017</b> , 38, 3341-3350	9.5	41
408	Impact of Aspirin and Clopidogrel Hyporesponsiveness in Patients Treated With Drug-Eluting Stents: 2-Year Results of a Prospective, Multicenter Registry Study. <i>JACC: Cardiovascular Interventions</i> , <b>2017</b> , 10, 1607-1617	5	21
407	2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 70, 3042-3067	15.1	228
406	Worsening atrioventricular conduction after hospital discharge in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: the HORIZONS-AMI trial. <i>Coronary Artery Disease</i> , <b>2017</b> , 28, 550-556	1.4	4
405	Long-term Safety and Efficacy of New-Generation Drug-Eluting Stents in Women With Acute Myocardial Infarction: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration. <i>JAMA Cardiology</i> , <b>2017</b> , 2, 855-862	16.2	18
404	Causes, Timing, and Impact of Dual Antiplatelet Therapy Interruption for Surgery (from the Patterns of Non-adherence to Anti-platelet Regimens In Stented Patients Registry). <i>American Journal of Cardiology</i> , <b>2017</b> , 120, 904-910	3	7
403	Reperfusion strategies in acute myocardial infarction and multivessel disease. <i>Nature Reviews Cardiology</i> , <b>2017</b> , 14, 665-678	14.8	36

402	Classification and patterns of bifurcation in-stent restenosis (BISR) in the second generation drug eluting stent era. <i>Hellenic Journal of Cardiology</i> , <b>2017</b> , 58, 167-168	2.1	1
401	Short-versus long-term Dual Antiplatelet therapy after drug-eluting stent implantation in women versus men: A sex-specific patient-level pooled-analysis of six randomized trials. <i>Catheterization and Cardiovascular Interventions</i> , <b>2017</b> , 89, 178-189	2.7	11
400	Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: Results From the PARIS Registry. <i>Catheterization and Cardiovascular Interventions</i> , <b>2017</b> , 89, E217-E225	2.7	10
399	Quantitative angiographic characterisation of coronary artery disease in patients with human immunodeficiency virus (HIV) infection undergoing percutaneous coronary intervention. <i>EuroIntervention</i> , <b>2017</b> , 12, 1757-1765	3.1	6
398	The DELTA 2 Registry: A Multicenter Registry Evaluating Percutaneous Coronary Intervention With New-Generation Drug-Eluting Stents in Patients With Obstructive Left Main Coronary Artery Disease. <i>JACC: Cardiovascular Interventions</i> , <b>2017</b> , 10, 2401-2410	5	25
397	Effect of Baseline Thrombocytopenia on Ischemic Outcomes in Patients With Acute Coronary Syndromes Who Undergo Percutaneous Coronary Intervention. <i>Canadian Journal of Cardiology</i> , <b>2016</b> , 32, 226-33	3.8	38
396	Incidence and impact of acute kidney injury in patients with acute coronary syndromes treated with coronary artery bypass grafting: Insights from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) and Acute Catheterization and Urgent Intervention Triage Strategy (ACUTE-III) trials. <i>American Heart Journal</i> , <b>2016</b> , 171, 40-7	4.9	24
395	Rationale and design of Apo-I Event Reduction in Ischemic Syndromes I (AEGIS-I): A phase 2b, randomized, placebo-controlled, dose-ranging trial to investigate the safety and tolerability of CSL112, a reconstituted, infusible, human apoA-I, after acute myocardial infarction. <i>American Heart Journal</i> , <b>2016</b> , 186, 22-8	4.9	23
394	Sex-Based Differences in Cessation of Dual-Antiplatelet Therapy Following Percutaneous Coronary Intervention With Stents. <i>JACC: Cardiovascular Interventions</i> , <b>2016</b> , 9, 1461-9	5	27
393	Neurological Outcomes With Embolic Protection Devices in Patients Undergoing Transcatheter Aortic Valve Replacement: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>JACC: Cardiovascular Interventions</i> , <b>2016</b> , 9, 2124-2133	5	45
392	Gender Differences in Associations Between Intraprocedural Thrombotic Events During Percutaneous Coronary Intervention and Adverse Outcomes. <i>American Journal of Cardiology</i> , <b>2016</b> , 118, 1661-1668	3	5
391	Genetic Risk, Adherence to a Healthy Lifestyle, and Coronary Disease. <i>New England Journal of Medicine</i> , <b>2016</b> , 375, 2349-2358	59.2	601
390	Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. <i>New England Journal of Medicine</i> , <b>2016</b> , 375, 2423-2434	59.2	929
389	Everolimus-Eluting Stents or Bypass Surgery for Left Main Coronary Artery Disease. <i>New England Journal of Medicine</i> , <b>2016</b> , 375, 2223-2235	59.2	603
388	Impact of an integrated treatment algorithm based on platelet function testing and clinical risk assessment: results of the TRIAGE Patients Undergoing Percutaneous Coronary Interventions To Improve Clinical Outcomes Through Optimal Platelet Inhibition study. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2016</b> , 42, 186-96	5.1	2
387	Prediction of 1-year mortality and impact of bivalirudin therapy according to level of baseline risk: A patient-level pooled analysis from three randomized trials. <i>Catheterization and Cardiovascular Interventions</i> , <b>2016</b> , 87, 391-400	2.7	7
386	Which Intraprocedural Thrombotic Events Impact Clinical Outcomes After Percutaneous Coronary Intervention in Acute Coronary Syndromes?: A Pooled Analysis of the HORIZONS-AMI and ACUTE Trials. <i>JACC: Cardiovascular Interventions</i> , <b>2016</b> , 9, 331-337	5	14
385	Sex Difference in Chest Pain After Implantation of Newer Generation Coronary Drug-Eluting Stents: A Patient-Level Pooled Analysis From the TWENTE and DUTCH PEERS Trials. <i>JACC: Cardiovascular Interventions</i> , <b>2016</b> , 9, 553-61	5	14

384	Polymer-Free Biolimus A9-Coated Stents in the Treatment of De Novo Coronary Lesions: 4- and 12-Month Angiographic Follow-Up and Final 5-Year Clinical Outcomes of the Prospective, Multicenter BioFreedom FIM Clinical Trial. <i>JACC: Cardiovascular Interventions</i> , <b>2016</b> , 9, 51-64	5	55
383	Drug-eluting stents and drug-eluting balloons are the best strategies to treat coronary in-stent restenosis. <i>Evidence-Based Medicine</i> , <b>2016</b> , 21, 90		2
382	Pretreatment with aspirin in acute coronary syndromes: Lessons from the ACUITY and HORIZONS-AMI trials. <i>European Heart Journal: Acute Cardiovascular Care</i> , <b>2016</b> , 5, 449-54	4.3	8
381	Safety and Efficacy of New-Generation Drug-Eluting Stents in Women at High Risk for Atherothrombosis: From the Women in Innovation and Drug-Eluting Stents Collaborative Patient-Level Pooled Analysis. <i>Circulation: Cardiovascular Interventions</i> , <b>2016</b> , 9, e002995	6	9
380	Impact of Bleeding and Bivalirudin Therapy on Mortality Risk in Women Undergoing Percutaneous Coronary Intervention (from the REPLACE-2, ACUITY, and HORIZONS-AMI Trials). <i>American Journal of Cardiology</i> , <b>2016</b> , 117, 186-91	3	26
379	Risk stratification of patients undergoing medical therapy after coronary angiography. <i>European Heart Journal</i> , <b>2016</b> , 37, 3103-3110	9.5	6
378	Impact of Hemoglobin A1c Levels on Residual Platelet Reactivity and Outcomes After Insertion of Coronary Drug-Eluting Stents (from the ADAPT-DES Study). <i>American Journal of Cardiology</i> , <b>2016</b> , 117, 192-200	3	12
377	2015 ACC/AHA/SCAI Focused Update on Primary Percutaneous Coronary Intervention for Patients With ST-Elevation Myocardial Infarction: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention and the 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , <b>2016</b> , 67, 1235-1250	15.1	491
376	Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial. <i>Lancet, The</i> , <b>2016</b> , 387, 349-356	40	87
375	Long-term clinical outcomes after percutaneous coronary intervention versus coronary artery bypass grafting for acute coronary syndrome from the DELTA registry: a multicentre registry evaluating percutaneous coronary intervention versus coronary artery bypass grafting for left main coronary artery disease. <i>European Heart Journal</i> , <b>2016</b> , 37, 622-31	3.1	12
374	Impact of time to treatment on the effects of bivalirudin vs. glycoprotein IIb/IIIa inhibitors and heparin in patients undergoing primary percutaneous coronary intervention: insights from the HORIZONS-AMI trial. <i>EuroIntervention</i> , <b>2016</b> , 12, 1144-1153	3.1	1
373	Preventing Contrast-induced Renal Failure: A Guide. <i>Interventional Cardiology Review</i> , <b>2016</b> , 11, 98-104	4.2	19
372	Time-Dependent Associations Between Actionable Bleeding, Coronary Thrombotic Events, and Mortality Following Percutaneous Coronary Intervention: Results From the PARIS Registry. <i>JACC: Cardiovascular Interventions</i> , <b>2016</b> , 9, 1349-57	5	36
371	Women in interventional cardiology: Update in percutaneous coronary intervention practice patterns and outcomes of female operators from the National Cardiovascular Data Registry. <i>Catheterization and Cardiovascular Interventions</i> , <b>2016</b> , 87, 663-8	2.7	21
370	Impact of anticoagulation regimen prior to revascularization in patients with non-ST-segment elevation acute coronary syndromes: The ACUITY trial. <i>Catheterization and Cardiovascular Interventions</i> , <b>2016</b> , 88, 174-81	2.7	2
369	Resistant in-stent restenosis in the drug eluting stent era. <i>Catheterization and Cardiovascular Interventions</i> , <b>2016</b> , 88, 777-785	2.7	10
368	The Impact of Timing of Ischemic and Hemorrhagic Events on Mortality After Percutaneous Coronary Intervention: The ADAPT-DES Study. <i>JACC: Cardiovascular Interventions</i> , <b>2016</b> , 9, 1450-7	5	20
367	The Optimal Duration of Dual Antiplatelet Therapy After PCI <b>2016</b> , 436-442		

366	Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction: The AEGIS-I Trial (ApoA-I Event Reducing in Ischemic Syndromes I). <i>Circulation</i> , <b>2016</b> , 134, 1918-1930	16.7	110
365	2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Journal of the American College of Cardiology</i> , <b>2016</b> , 67, 1232-1277	15.1	856
364	Relation Between Platelet Count and Platelet Reactivity to Thrombotic and Bleeding Risk: From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Study. <i>American Journal of Cardiology</i> , <b>2016</b> , 117, 1703-13	3	14
363	Sex-Based Differences in Acute Coronary Syndromes: Insights From Invasive and Noninvasive Coronary Technologies. <i>JACC: Cardiovascular Imaging</i> , <b>2016</b> , 9, 451-64	8.4	24
362	Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI undergoing primary PCI: An updated meta-analysis of 10,350 patients from five randomized clinical trials. <i>European Heart Journal: Acute Cardiovascular Care</i> , <b>2016</b> , 5, 253-62	4.3	43
361	Early Stent Thrombosis and Mortality After Primary Percutaneous Coronary Intervention in ST-Segment-Elevation Myocardial Infarction: A Patient-Level Analysis of 2 Randomized Trials. <i>Circulation: Cardiovascular Interventions</i> , <b>2016</b> , 9, e003272	6	8
360	Optimal P2Y12 Inhibitor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Network Meta-Analysis. <i>JACC: Cardiovascular Interventions</i> , <b>2016</b> , 9, 1036-46	5	35
359	Comparisons of the uptake and in-hospital outcomes associated with second-generation drug-eluting stents between men and women: results from the CathPCI Registry. <i>Coronary Artery Disease</i> , <b>2016</b> , 27, 442-8	1.4	8
358	Safety and Efficacy of New-Generation Drug-Eluting Stents in Women Undergoing Complex Percutaneous Coronary Artery Revascularization: From the WIN-DES Collaborative Patient-Level Pooled Analysis. <i>JACC: Cardiovascular Interventions</i> , <b>2016</b> , 9, 674-84	5	35
357	Cerebral Embolism During Transcatheter Aortic Valve Replacement: The BRAVO-3 MRI Study. <i>Journal of the American College of Cardiology</i> , <b>2016</b> , 68, 589-599	15.1	35
356	Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents: Risk Scores From PARIS. <i>Journal of the American College of Cardiology</i> , <b>2016</b> , 67, 2224-2234	15.1	306
355	Safety and Efficacy of Bivalirudin in Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention: From the REPLACE-2, ACUITY and HORIZONS-AMI Trials. <i>American Journal of Cardiology</i> , <b>2016</b> , 118, 6-16	3	4
354	Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study. <i>American Heart Journal</i> , <b>2016</b> , 182, 125-134	4.9	84
353	Acute and 30-Day Outcomes in Women After TAVR: Results From the WIN-TAVI (Women's International Transcatheter Aortic Valve Implantation) Real-World Registry. <i>JACC: Cardiovascular Interventions</i> , <b>2016</b> , 9, 1589-600	5	56
352	Evaluation and treatment of patients with lower extremity peripheral artery disease: consensus definitions from Peripheral Academic Research Consortium (PARC). <i>Journal of the American College of Cardiology</i> , <b>2015</b> , 65, 931-41	15.1	190
351	Clinical Trial Design Principles and Endpoint Definitions for Transcatheter Mitral Valve Repair and Replacement: Part 2: Endpoint Definitions: A Consensus Document From the Mitral Valve Academic Research Consortium. <i>Journal of the American College of Cardiology</i> , <b>2015</b> , 66, 308-321	15.1	268
350	The Ideal Anticoagulation Strategy in ST-Elevation Myocardial Infarction. <i>Progress in Cardiovascular Diseases</i> , <b>2015</b> , 58, 247-59	8.5	7
349	Clinical trial design principles and endpoint definitions for transcatheter mitral valve repair and replacement: part 2: endpoint definitions: A consensus document from the Mitral Valve Academic Research Consortium. <i>European Heart Journal</i> , <b>2015</b> , 36, 1878-91	9.5	70



348	2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards). <i>Journal of the American College of Cardiology</i> , <b>2015</b> , 66, 403-69	15.1	302
347	Gender-specific outcomes after balloon aortic valvuloplasty: Inhospital and long-term outcomes. <i>American Heart Journal</i> , <b>2015</b> , 170, 180-6	4.9	9
346	Cerebrovascular events after a primary percutaneous coronary intervention strategy for acute ST-segment-elevation myocardial infarction: analysis from the HORIZONS-AMI Trial. <i>Circulation: Cardiovascular Interventions</i> , <b>2015</b> , 8,	6	1
345	Age-related effects of smoking on coronary artery disease assessed by gray scale and virtual histology intravascular ultrasound. <i>American Journal of Cardiology</i> , <b>2015</b> , 115, 1056-62	3	10
344	Balancing the Risk of Bleeding and Stroke in Patients With Atrial Fibrillation After Percutaneous Coronary Intervention (from the AVIATOR Registry). <i>American Journal of Cardiology</i> , <b>2015</b> , 116, 37-42	3	25
343	Prevalence, impact, and predictive value of detecting subclinical coronary and carotid atherosclerosis in asymptomatic adults: the BiImage study. <i>Journal of the American College of Cardiology</i> , <b>2015</b> , 65, 1065-74	15.1	256
342	Fixed and Modifiable Correlates of Drug-Eluting Stent Thrombosis From a Large All-Comers Registry: Insights From ADAPT-DES. <i>Circulation: Cardiovascular Interventions</i> , <b>2015</b> , 8,	6	8
341	Usefulness of the Left Anterior Descending Coronary Artery Wrapping Around the Left Ventricular Apex to Predict Adverse Clinical Outcomes in Patients With Anterior Wall ST-Segment Elevation Myocardial Infarction (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction Trial). <i>Circulation</i> , <b>2015</b> , 132, 1478-87	3	12
340	Proton Pump Inhibitors, Platelet Reactivity, and Cardiovascular Outcomes After Drug-Eluting Stents in Clopidogrel-Treated Patients: The ADAPT-DES Study. <i>Circulation: Cardiovascular Interventions</i> , <b>2015</b> , 8,	6	34
339	Duration of Dual Antiplatelet Therapy After Coronary Stenting: A Review of the Evidence. <i>Journal of the American College of Cardiology</i> , <b>2015</b> , 66, 832-847	15.1	90
338	2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards). <i>Journal of Nuclear Cardiology</i> , <b>2015</b> , 22, 1041-144	2.1	25
337	Incidence, Predictors, and Impact of Post-Discharge Bleeding After Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , <b>2015</b> , 66, 1036-45	15.1	239
336	Stable coronary artery disease: revascularisation and invasive strategies. <i>Lancet, The</i> , <b>2015</b> , 386, 702-13	40	108
335	Impact of Contrast-Induced Acute Kidney Injury After Percutaneous Coronary Intervention on Short- and Long-Term Outcomes: Pooled Analysis From the HORIZONS-AMI and ACUITY Trials. <i>Circulation: Cardiovascular Interventions</i> , <b>2015</b> , 8, e002475	6	97
334	Sex-based differences in bleeding and long term adverse events after percutaneous coronary intervention for acute myocardial infarction: three year results from the HORIZONS-AMI trial. <i>Catheterization and Cardiovascular Interventions</i> , <b>2015</b> , 85, 359-68	2.7	80
333	SYNTAX score and the risk of stent thrombosis after percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: an ACUITY trial substudy. <i>Catheterization and Cardiovascular Interventions</i> , <b>2015</b> , 85, 1-10	2.7	25
332	Outcomes of patients calling emergency medical services for suspected acute cardiovascular disease. <i>American Journal of Cardiology</i> , <b>2015</b> , 115, 13-20	3	12
331	Clinical and angiographic evaluation of the resolute zotarolimus-eluting coronary stent in Japanese patients [long-term outcome in the RESOLUTE Japan and RESOLUTE Japan small vessel study. <i>Circulation Journal</i> , <b>2015</b> , 79, 96-103	2.9	22

330	Reperfusion in women with STEMI: a date not to be late!. <i>Revista Brasileira De Cardiologia Invasiva (English Edition)</i> , <b>2015</b> , 23, 4-5		
329	New-generation drug-eluting stents reduce stent thrombosis and myocardial infarction: a propensity-score-adjusted analysis from the multicenter REAL registry (REgistro Regionale AngiopLastiche Dell'Emilia-Romagna). <i>Catheterization and Cardiovascular Interventions</i> , <b>2015</b> , 85, 797-806	2.7	4
328	Femoral vascular closure device use, bivalirudin anticoagulation, and bleeding after primary angioplasty for STEMI: results from the HORIZONS-AMI trial. <i>Catheterization and Cardiovascular Interventions</i> , <b>2015</b> , 85, 371-9	2.7	12
327	Prevalence and impact of high platelet reactivity in chronic kidney disease: results from the Assessment of Dual Antiplatelet Therapy with Drug-Eluting Stents registry. <i>Circulation: Cardiovascular Interventions</i> , <b>2015</b> , 8, e001683	6	47
326	Morphological changes and clinical impact of unstable plaques within untreated segments of acute myocardial infarction patients during a 3-year follow-up: an analysis from the HORIZONS-AMI trial. <i>Coronary Artery Disease</i> , <b>2015</b> , 26, 469-75	1.4	4
325	Cost implications of intraprocedural thrombotic events during PCI. <i>Catheterization and Cardiovascular Interventions</i> , <b>2015</b> , 86, 30-9	2.7	3
324	Accuracy of bleeding scores for patients presenting with myocardial infarction: a meta-analysis of 9 studies and 13 759 patients. <i>Postępy W Kardiologii Interwencyjnej</i> , <b>2015</b> , 11, 182-90	0.4	7
323	The relationship among extent of lipid-rich plaque, lesion characteristics, and plaque progression/regression in patients with coronary artery disease: a serial near-infrared spectroscopy and intravascular ultrasound study. <i>European Heart Journal Cardiovascular Imaging</i> , <b>2015</b> , 16, 81-7	4.1	26
322	Surgical versus percutaneous coronary revascularization for multivessel disease in diabetic patients with non-ST-segment-elevation acute coronary syndrome: analysis from the Acute Catheterization and Early Intervention Triage Strategy trial. <i>Circulation: Cardiovascular Interventions</i> , <b>2015</b> , 8,	6	18
321	Is There an Ideal Level of Platelet P2Y12-Receptor Inhibition in Patients Undergoing Percutaneous Coronary Intervention?: "Window" Analysis From the ADAPT-DES Study (Assessment of Dual AntiPlatelet Therapy With Drug-Eluting Stents). <i>JACC: Cardiovascular Interventions</i> , <b>2015</b> , 8, 1978-1987	5	22
320	Antithrombotic strategy variability in Atrial fibrillation and obstructive coronary disease revascularized with PCI-rationale and study design of the prospective observational multicenter AVIATOR 2 registry. <i>American Heart Journal</i> , <b>2015</b> , 170, 1234-42	4.9	3
319	Bivalirudin Versus Heparin Anticoagulation in Transcatheter Aortic Valve Replacement: The Randomized BRAVO-3 Trial. <i>Journal of the American College of Cardiology</i> , <b>2015</b> , 66, 2860-2868	15.1	88
318	Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI undergoing primary percutaneous coronary intervention: pooled patient-level analysis from the HORIZONS-AMI and EUROMAX trials. <i>Journal of the American College of Cardiology</i> , <b>2015</b> , 65, 27-38	15.1	54
317	2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards). <i>Circulation</i> , <b>2015</b> , 132, 362-61	16.7	176
316	Follow the data: bivalirudin (and not heparin alone) during percutaneous coronary intervention provides the best clinical outcomes. <i>JACC: Cardiovascular Interventions</i> , <b>2015</b> , 8, 225-227	5	5
315	Antiplatelet therapy after drug-eluting stent implantation. <i>Journal of Cardiology</i> , <b>2015</b> , 65, 98-104	3	6
314	Incidence and impact of totally occluded culprit coronary arteries in patients presenting with non-ST-segment elevation myocardial infarction. <i>American Journal of Cardiology</i> , <b>2015</b> , 115, 428-33	3	18
313	Predictors and impact of target vessel revascularization after stent implantation for acute ST-segment elevation myocardial infarction: lessons from HORIZONS-AMI. <i>American Heart Journal</i> , <b>2015</b> , 169, 242-8	4.9	9

312	Duration of dual antiplatelet therapy after drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials. <i>Journal of the American College of Cardiology</i> , <b>2015</b> , 65, 1298-1310	15.1	252
311	An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI). <i>American Heart Journal</i> , <b>2015</b> , 169, 472-8.e5	4.9	114
310	Incidence, predictors, and impact of neurological events in non-ST-segment elevation acute coronary syndromes: the ACUITY trial. <i>EuroIntervention</i> , <b>2015</b> , 11, 399-406	3.1	5
309	Reasonable incomplete revascularisation after percutaneous coronary intervention: the SYNTAX Revascularisation Index. <i>EuroIntervention</i> , <b>2015</b> , 11, 634-42	3.1	21
308	Interventional Management of Diabetic Coronaropathy and Diffuse Coronary Artery Disease <b>2015</b> , 2253-2270		
307	Usefulness of the SYNTAX score to predict acute kidney injury after percutaneous coronary intervention (from the Acute Catheterization and Urgent Intervention Triage Strategy Trial). <i>American Journal of Cardiology</i> , <b>2014</b> , 113, 1331-7	3	17
306	D-dimer levels predict ischemic and hemorrhagic outcomes after acute myocardial infarction: a HORIZONS-AMI biomarker substudy. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2014</b> , 37, 155-64	5.1	38
305	Impact of cigarette smoking on extent of coronary artery disease and prognosis of patients with non-ST-segment elevation acute coronary syndromes: an analysis from the ACUITY Trial (Acute Catheterization and Urgent Intervention Triage Strategy). <i>JACC: Cardiovascular Interventions</i> , <b>2014</b> , 7, 372-9	5	34
304	Contrast-induced acute kidney injury after primary percutaneous coronary intervention: results from the HORIZONS-AMI substudy. <i>European Heart Journal</i> , <b>2014</b> , 35, 1533-40	9.5	164
303	Comparison of prasugrel and bivalirudin vs clopidogrel and heparin in patients with ST-segment elevation myocardial infarction: Design and rationale of the Bavarian Reperfusion Alternatives Evaluation (BRAVE) 4 trial. <i>Clinical Cardiology</i> , <b>2014</b> , 37, 270-6	3.3	15
302	Prognostic value of access site and nonaccess site bleeding after percutaneous coronary intervention: a cohort study in ST-segment elevation myocardial infarction and comprehensive meta-analysis. <i>JACC: Cardiovascular Interventions</i> , <b>2014</b> , 7, 622-30	5	23
301	Prospective validation of the Bleeding Academic Research Consortium classification in the all-comer PRODIGY trial. <i>European Heart Journal</i> , <b>2014</b> , 35, 2524-9	9.5	39
300	Reduction in cardiac mortality with bivalirudin in patients with and without major bleeding: The HORIZONS-AMI trial (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction). <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 63, 15-20	15.1	56
299	Relationship between intravascular ultrasound guidance and clinical outcomes after drug-eluting stents: the assessment of dual antiplatelet therapy with drug-eluting stents (ADAPT-DES) study. <i>Circulation</i> , <b>2014</b> , 129, 463-70	16.7	267
298	Impact of atrial fibrillation in patients with ST-elevation myocardial infarction treated with percutaneous coronary intervention (from the HORIZONS-AMI [Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction] trial). <i>American Journal of Cardiology</i> , <b>2014</b> , 113, 235-42	3	63
297	Association between intraprocedural thrombotic events and adverse outcomes after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction (a Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction [HORIZONS-AMI] Substudy). <i>American Journal of Cardiology</i> , <b>2014</b> , 113, 36-43	3	23
296	The impact of the coronary collateral circulation on outcomes in patients with acute coronary syndromes: results from the ACUITY trial. <i>Heart</i> , <b>2014</b> , 100, 647-51	5.1	18
295	Incidence, predictors, and implications of reinfarction after primary percutaneous coronary intervention in ST-segment-elevation myocardial infarction: the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction Trial. <i>Circulation: Cardiovascular Interventions</i> , <b>2014</b> , 7, 543-51	6	49

294	Balancing ischaemia and bleeding risks with novel oral anticoagulants. <i>Nature Reviews Cardiology</i> , <b>2014</b> , 11, 693-703	14.8	20
293	Procedural variation in the performance of primary percutaneous coronary intervention for ST-elevation myocardial infarction: a SCAI-based survey study of US interventional cardiologists. <i>Catheterization and Cardiovascular Interventions</i> , <b>2014</b> , 83, 721-6	2.7	19
292	Stent thrombosis: a clinical perspective. <i>JACC: Cardiovascular Interventions</i> , <b>2014</b> , 7, 1081-92	5	107
291	Prognosis of patients with non-ST-segment-elevation myocardial infarction and nonobstructive coronary artery disease: propensity-matched analysis from the Acute Catheterization and Urgent Intervention Triage Strategy trial. <i>Circulation: Cardiovascular Interventions</i> , <b>2014</b> , 7, 285-93	6	108
290	Clustering of acute and subacute stent thrombosis related to the introduction of generic clopidogrel. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , <b>2014</b> , 19, 201-8	2.6	12
289	Postprocedural anticoagulation for specific therapeutic indications after revascularization for ST-segment elevation myocardial infarction (from the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction Trial). <i>American Journal of Cardiology</i> , <b>2014</b> , 114, 1322-6	3	3
288	Contemporary overview and clinical perspectives of chronic total occlusions. <i>Nature Reviews Cardiology</i> , <b>2014</b> , 11, 458-69	14.8	28
287	Impact of delay to reperfusion on reperfusion success, infarct size, and clinical outcomes in patients with ST-segment elevation myocardial infarction: the INFUSE-AMI Trial (INFUSE-Anterior Myocardial Infarction). <i>JACC: Cardiovascular Interventions</i> , <b>2014</b> , 7, 733-40	5	38
286	Bleeding Definitions <b>2014</b> , 259-265		
285	Meta-analysis of randomized trials comparing the effectiveness of different strategies for the treatment of drug-eluting stent restenosis. <i>American Journal of Cardiology</i> , <b>2014</b> , 114, 1339-46	3	22
284	Comparison of outcomes in patients with ST-segment elevation myocardial infarction discharged on versus not on statin therapy (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction Trial). <i>American Journal of Cardiology</i> , <b>2014</b> , 113, 1273-9	3	10
283	Impact of major bleeding on long-term mortality in anemic versus nonanemic patients undergoing percutaneous coronary intervention using bivalirudin. <i>American Journal of Cardiology</i> , <b>2014</b> , 113, 1481-6 <sup>3</sup>		9
282	A registry-based randomized trial comparing radial and femoral approaches in women undergoing percutaneous coronary intervention: the SAFE-PCI for Women (Study of Access Site for Enhancement of PCI for Women) trial. <i>JACC: Cardiovascular Interventions</i> , <b>2014</b> , 7, 857-67	5	168
281	Randomized comparison between 3-month Cre8 DES vs. 1-month Vision/Multilink8 BMS neointimal coverage assessed by OCT evaluation: the DEMONSTRATE study. <i>International Journal of Cardiology</i> , <b>2014</b> , 176, 904-9	3.2	28
280	Impact of pre-procedural cardiopulmonary instability in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction Trial). <i>American Journal of Cardiology</i> , <b>2014</b> , 114, 962-7	3	2
279	Prasugrel plus bivalirudin vs. clopidogrel plus heparin in patients with ST-segment elevation myocardial infarction. <i>European Heart Journal</i> , <b>2014</b> , 35, 2285-94	9.5	79
278	Dedicated two-stent technique in complex bifurcation percutaneous coronary intervention with use of everolimus-eluting stents: the EES-bifurcation study. <i>International Journal of Cardiology</i> , <b>2014</b> , 174, 13-7	3.2	5
277	Comparative effectiveness of upstream glycoprotein IIb/IIIa inhibitors in patients with moderate- and high-risk acute coronary syndromes: an Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) substudy. <i>American Heart Journal</i> , <b>2014</b> , 167, 43-50	4.9	7

276	Impact of coronary lesion complexity on drug-eluting stent outcomes in patients with and without diabetes mellitus: analysis from 18 pooled randomized trials. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 63, 2111-2118	15.1	64
275	Outcomes in patients with ST-segment elevation acute myocardial infarction treated with clopidogrel versus prasugrel (from the INFUSE-AMI trial). <i>American Journal of Cardiology</i> , <b>2014</b> , 113, 1457-60	3	32
274	Impact of multiple complex plaques on short- and long-term clinical outcomes in patients presenting with ST-segment elevation myocardial infarction (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction [HORIZONS-AMI] Trial). <i>American Journal of Cardiology</i> , <b>2014</b> , 113, 1621-7	3	9
273	Relation between coronary calcium and major bleeding after percutaneous coronary intervention in acute coronary syndromes (from the Acute Catheterization and Urgent Intervention Triage Strategy and Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction Trial). <i>American Journal of Cardiology</i> , <b>2014</b> , 113, 886-7	3	18
272	Prognostic utility of the SYNTAX score in patients with single versus multivessel disease undergoing percutaneous coronary intervention (from the Acute Catheterization and Urgent Intervention Triage Strategy [ACUITY] trial). <i>American Journal of Cardiology</i> , <b>2014</b> , 113, 203-10	3	34
271	Relation of C-reactive protein levels to instability of untreated vulnerable coronary plaques (from the PROSPECT Study). <i>American Journal of Cardiology</i> , <b>2014</b> , 114, 376-83	3	20
270	Ticagrelor reduces thrombus formation more than clopidogrel, even when co-administered with bivalirudin. <i>Thrombosis and Haemostasis</i> , <b>2014</b> , 112, 1069-70	7	3
269	Acute Coronary Syndrome <b>2014</b> , 1-8		
268	Stroke after transcatheter aortic valve replacement: incidence, risk factors, prognosis, and preventive strategies. <i>Clinical Cardiology</i> , <b>2014</b> , 37, 756-64	3.3	55
267	The prognostic importance of left ventricular function in patients with ST-segment elevation myocardial infarction: the HORIZONS-AMI trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , <b>2014</b> , 3, 67-77	4.3	49
266	Incidence and angiographic characteristics of patients with apical ballooning syndrome (takotsubo/stress cardiomyopathy) in the HORIZONS-AMI trial: an analysis from a multicenter, international study of ST-elevation myocardial infarction. <i>Catheterization and Cardiovascular Interventions</i> , <b>2014</b> , 83, 343-9	2.7	61
265	The use of vascular closure devices and impact on major bleeding and net adverse clinical events (NACEs) in balloon aortic valvuloplasty: a sub-analysis of the BRAVO study. <i>Catheterization and Cardiovascular Interventions</i> , <b>2014</b> , 83, 148-53	2.7	14
264	Clinical profile and impact of family history of premature coronary artery disease on clinical outcomes of patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction: analysis from the HORIZONS-AMI Trial. <i>Cardiovascular Revascularization Medicine</i> , <b>2014</b> , 15, 375-80	1.6	8
263	Compensatory enlargement of the left main coronary artery: insights from the PROSPECT study. <i>Coronary Artery Disease</i> , <b>2014</b> , 25, 98-103	1.4	11
262	Long-term outcomes of percutaneous coronary interventions or coronary artery bypass grafting for left main coronary artery disease in octogenarians (from a Drug-Eluting stent for Left main Artery registry substudy). <i>American Journal of Cardiology</i> , <b>2014</b> , 113, 2007-12	3	23
261	Body mass index and acute and long-term outcomes after acute myocardial infarction (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction Trial). <i>American Journal of Cardiology</i> , <b>2014</b> , 114, 9-16	3	29
260	Ischemic outcomes after coronary intervention of calcified vessels in acute coronary syndromes. Pooled analysis from the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) and ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) TRIALS. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 63, 1845-54	15.1	232
259	Long-term clinical outcomes after percutaneous coronary intervention versus coronary artery bypass grafting for ostial/midshaft lesions in unprotected left main coronary artery from the DELTA registry: a multicenter registry evaluating percutaneous coronary intervention versus coronary artery bypass grafting for left main treatment. <i>Catheterization and Cardiovascular Interventions</i> , <b>2014</b> , 7, 354-61	5	38

258	Consideration of a new definition of clinically relevant myocardial infarction after coronary revascularization: an expert consensus document from the Society for Cardiovascular Angiography and Interventions (SCAI). <i>Catheterization and Cardiovascular Interventions</i> , <b>2014</b> , 83, 27-36	2.7	50
257	Effect of bivalirudin on aortic valve intervention outcomes study: a two-centre registry study comparing bivalirudin and unfractionated heparin in balloon aortic valvuloplasty. <i>EuroIntervention</i> , <b>2014</b> , 10, 312-9	3.1	20
256	Benefits of optimising coronary flow before stenting in primary percutaneous coronary intervention for ST-elevation myocardial infarction: insights from INFUSE-AMI. <i>EuroIntervention</i> , <b>2014</b> , 9, 1195-201	3.1	14
255	Use of the REG1 anticoagulation system in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the phase II RADAR-PCI study. <i>EuroIntervention</i> , <b>2014</b> , 10, 431-8	3.1	22
254	Interventional Management of Diabetic Coronaropathy and Diffuse Coronary Artery Disease <b>2014</b> , 1-20		
253	Relationship between the intensity of heparin anticoagulation and clinical outcomes in patients receiving glycoprotein IIb/IIIa inhibitors during primary percutaneous coronary intervention in acute myocardial infarction. <i>Catheterization and Cardiovascular Interventions</i> , <b>2013</b> , 81, E9-14	2.7	6
252	Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. <i>Lancet, The</i> , <b>2013</b> , 382, 1714-22	4.0	405
251	Current periprocedural anticoagulation in transcatheter aortic valve replacement: could bivalirudin be an option? Rationale and design of the BRAVO 2/3 studies. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2013</b> , 35, 483-93	5.1	22
250	Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. <i>Lancet, The</i> , <b>2013</b> , 382, 614-23	4.0	606
249	Non-fibroatheroma lesion phenotype and long-term clinical outcomes: a substudy analysis from the PROSPECT study. <i>JACC: Cardiovascular Imaging</i> , <b>2013</b> , 6, 908-16	8.4	37
248	Complementary prognostic utility of myocardial blush grade and ST-segment resolution after primary percutaneous coronary intervention: analysis from the HORIZONS-AMI trial. <i>American Heart Journal</i> , <b>2013</b> , 166, 676-83	4.9	20
247	Intra-procedural stent thrombosis: a new risk factor for adverse outcomes in patients undergoing percutaneous coronary intervention for acute coronary syndromes. <i>JACC: Cardiovascular Interventions</i> , <b>2013</b> , 6, 36-43	5	39
246	Dynamic nature of nonculprit coronary artery lesion morphology in STEMI: a serial IVUS analysis from the HORIZONS-AMI trial. <i>JACC: Cardiovascular Imaging</i> , <b>2013</b> , 6, 86-95	8.4	48
245	The REMEDEE trial: a randomized comparison of a combination sirolimus-eluting endothelial progenitor cell capture stent with a paclitaxel-eluting stent. <i>JACC: Cardiovascular Interventions</i> , <b>2013</b> , 6, 334-43	5	71
244	Antithrombotic outcome trials in acute coronary syndromes: seeking the optimal balance between safety and efficacy. <i>European Heart Journal</i> , <b>2013</b> , 34, 1621-9	9.5	8
243	Consideration of a new definition of clinically relevant myocardial infarction after coronary revascularization: an expert consensus document from the Society for Cardiovascular Angiography and Interventions (SCAI). <i>Journal of the American College of Cardiology</i> , <b>2013</b> , 62, 1563-70	15.1	351
242	Long-term clinical outcomes after percutaneous coronary intervention for ostial/mid-shaft lesions versus distal bifurcation lesions in unprotected left main coronary artery: the DELTA Registry (drug-eluting stent for left main coronary artery disease): a multicenter registry evaluating	5	61
241	Outcome of patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention during on- versus off-hours (a Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction [HORIZONS-AMI] trial substudy). <i>American Journal of Cardiology</i> , <b>2013</b> , 111, 916-54	3	23

240	Impact of the severity of coronary artery calcification on clinical events in patients undergoing coronary artery bypass grafting (from the Acute Catheterization and Urgent Intervention Triage Strategy Trial). <i>American Journal of Cardiology</i> , <b>2013</b> , 112, 1730-7	3	29
239	Clinical endpoint adjudication in a contemporary all-comers coronary stent investigation: methodology and external validation. <i>Contemporary Clinical Trials</i> , <b>2013</b> , 34, 53-9	2.3	8
238	Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. <i>Journal of Thoracic and Cardiovascular Surgery</i> , <b>2013</b> , 145, 6-23	1.5	647
237	Relationship between biomarkers and subsequent bleeding risk in ST-segment elevation myocardial infarction patients treated with paclitaxel-eluting stents: a HORIZONS-AMI substudy. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2013</b> , 35, 200-8	5.1	5
236	Balance of Ischemia and Bleeding in Selecting an Antithrombotic Regimen. <i>Interventional Cardiology Clinics</i> , <b>2013</b> , 2, 515-525	1.4	
235	The Optimal Duration of Dual Combination Antiplatelet Therapy After Stent Implantation and Perioperative Management Issues. <i>Interventional Cardiology Clinics</i> , <b>2013</b> , 2, 585-594	1.4	
234	Implications of pre-procedural TIMI flow in patients with non ST-segment elevation acute coronary syndromes undergoing percutaneous coronary revascularization: insights from the ACUITY trial. <i>International Journal of Cardiology</i> , <b>2013</b> , 167, 727-32	3.2	5
233	Embedding a randomized clinical trial into an ongoing registry infrastructure: unique opportunities for efficiency in design of the Study of Access site For Enhancement of Percutaneous Coronary Intervention for Women (SAFE-PCI for Women). <i>American Heart Journal</i> , <b>2013</b> , 166, 421-8	4.9	59
232	Safety and efficacy of drug-eluting stents in women: a patient-level pooled analysis of randomised trials. <i>Lancet, The</i> , <b>2013</b> , 382, 1879-88	40	102
231	Long-term prognosis of patients presenting with ST-segment elevation myocardial infarction with no significant coronary artery disease (from the HORIZONS-AMI trial). <i>American Journal of Cardiology</i> , <b>2013</b> , 111, 643-8	3	52
230	Impact of hyperglycemia in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: the HORIZONS-AMI trial. <i>International Journal of Cardiology</i> , <b>2013</b> , 167, 2572-9	3.2	51
229	Comparison of outcomes of patients with ST-segment elevation myocardial infarction with versus without previous coronary artery bypass grafting (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction [HORIZONS-AMI] trial). <i>American Journal of Cardiology</i> , <b>2013</b> , 111, 1277-84	3	18
228	Frequency, mechanisms, and implications of late peri-stent contrast staining: analysis (from the HORIZONS-AMI Trial). <i>American Journal of Cardiology</i> , <b>2013</b> , 111, 1587-92	3	7
227	Percutaneous recanalization of chronic total occlusions: wherein lies the body of proof?. <i>American Heart Journal</i> , <b>2013</b> , 165, 133-42	4.9	20
226	Characteristics and outcomes of patients with ST-segment elevation myocardial infarction excluded from the harmonizing outcomes with revascularization and stents in acute myocardial infarction (HORIZONS-AMI) trial. <i>American Journal of Cardiology</i> , <b>2013</b> , 111, 196-201	3	9
225	Antithrombotic treatment in transcatheter aortic valve implantation: insights for cerebrovascular and bleeding events. <i>Journal of the American College of Cardiology</i> , <b>2013</b> , 62, 2349-2359	15.1	126
224	Changes in plaque lipid content after short-term intensive versus standard statin therapy: the YELLOW trial (reduction in yellow plaque by aggressive lipid-lowering therapy). <i>Journal of the American College of Cardiology</i> , <b>2013</b> , 62, 21-9	15.1	151
223	Comparison of Three-year outcomes after primary percutaneous coronary intervention in patients with left ventricular ejection fraction . <i>American Journal of Cardiology</i> , <b>2013</b> , 111, 12-20	3	41

222	Association among leukocyte count, mortality, and bleeding in patients with non-ST-segment elevation acute coronary syndromes (from the Acute Catheterization and Urgent Intervention Triage Strategy [ACUITY] trial). <i>American Journal of Cardiology</i> , <b>2013</b> , 111, 1237-45	3	12
221	A Phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trial. <i>European Heart Journal</i> , <b>2013</b> , 34, 2481-9	9.5	70
220	Relationship between ST-segment recovery and clinical outcomes after primary percutaneous coronary intervention: the HORIZONS-AMI ECG substudy report. <i>Circulation: Cardiovascular Interventions</i> , <b>2013</b> , 6, 216-23	6	33
219	Leukocyte count is a modulating factor for the mortality benefit of bivalirudin in ST-segment-elevation acute myocardial infarction: the HORIZONS-AMI trial. <i>Circulation: Cardiovascular Interventions</i> , <b>2013</b> , 6, 518-26	6	15
218	Are adverse events following an invasive strategy in patients with non-ST-segment elevation acute coronary syndromes more frequent at US sites versus non-US sites? Analysis from the ACUITY trial. <i>Catheterization and Cardiovascular Interventions</i> , <b>2013</b> , 82, E365-74	2.7	2
217	Impact of advanced age on the safety and effectiveness of paclitaxel-eluting stent implantation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty: The HORIZONS-AMI trial. <i>Catheterization and Cardiovascular Interventions</i> , <b>2013</b> , 82, 869-77	2.7	11
216	Impact of scheduled angiographic follow-up in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. <i>Journal of Interventional Cardiology</i> , <b>2013</b> , 26, 319-24	1.8	9
215	Long-term clinical outcomes after percutaneous coronary intervention for chronic total occlusions in elderly patients (≥5 years): five-year outcomes from a 1,791 patient multi-national registry. <i>Catheterization and Cardiovascular Interventions</i> , <b>2013</b> , 82, 85-92	2.7	22
214	Coronary reperfusion and clinical outcomes after thrombus aspiration during primary percutaneous coronary intervention: findings from the HORIZONS-AMI trial. <i>Catheterization and Cardiovascular Interventions</i> , <b>2013</b> , 82, 594-601	2.7	8
213	2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. <i>Catheterization and Cardiovascular Interventions</i> , <b>2013</b> , 82, E366-355	2.7	81
212	Adverse event rates following primary PCI for STEMI at US and non-US hospitals: three-year analysis from the HORIZONS-AMI trial. <i>EuroIntervention</i> , <b>2013</b> , 8, 1134-42	3.1	37
211	Impact of infarct-related artery patency before primary PCI on outcome in patients with ST-segment elevation myocardial infarction: the HORIZONS-AMI trial. <i>EuroIntervention</i> , <b>2013</b> , 8, 1307-14	3.1	26
210	Predictors of suboptimal TIMI flow after primary angioplasty for acute myocardial infarction: results from the HORIZONS-AMI trial. <i>EuroIntervention</i> , <b>2013</b> , 9, 220-7	3.1	29
209	Three-year clinical results of the Axxess Biolimus A9 eluting bifurcation stent system: the DIVERGE study. <i>EuroIntervention</i> , <b>2013</b> , 9, 573-81	3.1	25
208	Impact of bifurcation target lesion on angiographic, electrocardiographic, and clinical outcomes of patients undergoing primary percutaneous coronary intervention (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction [HORIZONS-AMI] trial). <i>EuroIntervention</i> , <b>2013</b> , 9, 817-23	3.1	13
207	Coronary artery bypass graft versus percutaneous coronary intervention with drug-eluting stent implantation for diabetic patients with unprotected left main coronary artery disease: the D-DELTA registry. <i>EuroIntervention</i> , <b>2013</b> , 9, 803-8	3.1	2
206	A new score for risk stratification of patients with acute coronary syndromes undergoing percutaneous coronary intervention: the ACUITY-PCI (Acute Catheterization and Urgent Intervention Triage Strategy-Percutaneous Coronary Intervention) risk score. <i>JACC: Cardiovascular Interventions</i> , <b>2012</b> , 5, 1108-16	5	31
205	Inverse relationship between body mass index and coronary artery calcification in patients with clinically significant coronary lesions. <i>Atherosclerosis</i> , <b>2012</b> , 221, 176-82	3.1	41



204	Future Perspectives on Percutaneous Coronary Interventions in Women. <i>Interventional Cardiology Clinics</i> , <b>2012</b> , 1, 251-258	1.4	
203	The Use of Bivalirudin in ST-Segment Elevation Myocardial Infarction: Advantages and Limitations. <i>Interventional Cardiology Clinics</i> , <b>2012</b> , 1, 441-451	1.4	
202	Comparison of clinical and angiographic prognostic risk scores in patients with acute coronary syndromes: Analysis from the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial. <i>American Heart Journal</i> , <b>2012</b> , 163, 383-91, 391.e1-5	4.9	29
201	Impact of major bleeding and blood transfusions after cardiac surgery: analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. <i>American Heart Journal</i> , <b>2012</b> , 163, 522-9	4.9	52
200	Relation between angiographic lesion severity, vulnerable plaque morphology and future adverse cardiac events (from the Providing Regional Observations to Study Predictors of Events in the Coronary Tree study). <i>American Journal of Cardiology</i> , <b>2012</b> , 110, 471-7	3	35
199	Impact of the presence and extent of incomplete angiographic revascularization after percutaneous coronary intervention in acute coronary syndromes: the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial. <i>Circulation</i> , <b>2012</b> , 125, 2613-20	16.7	99
198	Does clinical presentation affect outcome among patients with acute coronary syndromes undergoing percutaneous coronary intervention? Insights from the Providing Regional Observations to Study Predictors of Events in the Coronary Tree study. <i>American Heart Journal</i> , <b>2012</b> , 164, 561-7	4.9	3
197	Clinical outcomes following stent thrombosis occurring in-hospital versus out-of-hospital: results from the HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) trial. <i>Journal of the American College of Cardiology</i> , <b>2012</b> , 59, 1752-9	15.1	48
196	Intraprocedural thrombotic events during percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes are associated with adverse outcomes: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. <i>Journal of the American College of Cardiology</i> , <b>2012</b> , 59, 1745-51	15.1	36
195	Quantification and impact of untreated coronary artery disease after percutaneous coronary intervention: the residual SYNTAX (Synergy Between PCI with Taxus and Cardiac Surgery) score. <i>Journal of the American College of Cardiology</i> , <b>2012</b> , 59, 2165-74	15.1	241
194	Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. <i>Journal of the American College of Cardiology</i> , <b>2012</b> , 60, 1438-54	15.1	1306
193	Drug-eluting stent for left main coronary artery disease. The DELTA registry: a multicenter registry evaluating percutaneous coronary intervention versus coronary artery bypass grafting for left main treatment. <i>JACC: Cardiovascular Interventions</i> , <b>2012</b> , 5, 718-27	5	102
192	Development and validation of a stent thrombosis risk score in patients with acute coronary syndromes. <i>JACC: Cardiovascular Interventions</i> , <b>2012</b> , 5, 1097-105	5	79
191	Safety and efficacy of high- versus low-dose aspirin after primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial. <i>JACC: Cardiovascular Interventions</i> , <b>2012</b> , 5, 1231-8	5	27
190	Coronary plaque composition, morphology, and outcomes in patients with and without chronic kidney disease presenting with acute coronary syndromes. <i>JACC: Cardiovascular Imaging</i> , <b>2012</b> , 5, S53-61	8.4	77
189	Residual plaque burden in patients with acute coronary syndromes after successful percutaneous coronary intervention. <i>JACC: Cardiovascular Imaging</i> , <b>2012</b> , 5, S76-85	8.4	34
188	Comparison of abciximab versus eptifibatide during percutaneous coronary intervention in ST-segment elevation myocardial infarction (from the HORIZONS-AMI trial). <i>American Journal of Cardiology</i> , <b>2012</b> , 110, 940-7	3	8
187	Coronary pressure-derived fractional flow reserve measurements: recommendations for standardization, recording, and reporting as a core laboratory technique. Proposals for integration in clinical trials. <i>Circulation: Cardiovascular Interventions</i> , <b>2012</b> , 5, 312-7	6	40

186	Correlation between index electrocardiographic patterns and pre-intervention angiographic findings: insights from the HORIZONS-AMI trial. <i>Catheterization and Cardiovascular Interventions</i> , <b>2012</b> , 79, 1092-8	2.7	19
185	The XIENCE nano everolimus eluting coronary stent system for the treatment of small coronary arteries: the SPIRIT Small Vessel trial. <i>Catheterization and Cardiovascular Interventions</i> , <b>2012</b> , 80, 546-53	2.7	37
184	2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. <i>Catheterization and Cardiovascular Interventions</i> , <b>2012</b> , 79, 453-95	2.7	121
183	Relationship between biomarkers and subsequent clinical and angiographic restenosis after paclitaxel-eluting stents for treatment of STEMI: a HORIZONS-AMI substudy. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2012</b> , 34, 165-79	5.1	10
182	Usefulness of minimum stent cross sectional area as a predictor of angiographic restenosis after primary percutaneous coronary intervention in acute myocardial infarction (from the HORIZONS-AMI Trial IVUS substudy). <i>American Journal of Cardiology</i> , <b>2012</b> , 109, 455-60	3	32
181	Prognostic significance of postprocedural sustained ventricular tachycardia or fibrillation in patients undergoing primary percutaneous coronary intervention (from the HORIZONS-AMI Trial). <i>American Journal of Cardiology</i> , <b>2012</b> , 109, 805-12	3	51
180	Outcomes of patients treated with triple antithrombotic therapy after primary percutaneous coronary intervention for ST-elevation myocardial infarction (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction [HORIZONS-AMI] trial). <i>American Journal of Cardiology</i> , <b>2012</b> , 109, 831-8	3	45
179	Diabetes mellitus, myocardial reperfusion, and outcome in patients with acute ST-elevation myocardial infarction treated with primary angioplasty (from HORIZONS AMI). <i>American Journal of Cardiology</i> , <b>2012</b> , 109, 1111-6	3	36
178	Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. <i>European Heart Journal</i> , <b>2012</b> , 33, 2403-18	9.5	706
177	Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document (VARC-2). <i>European Journal of Cardio-thoracic Surgery</i> , <b>2012</b> , 42, S45-60	3	554
176	Operator versus core laboratory assessment of angiographic reperfusion markers in patients undergoing primary percutaneous coronary intervention for ST-segment-elevation myocardial infarction. <i>Circulation: Cardiovascular Interventions</i> , <b>2012</b> , 5, 563-9	6	8
175	Long-term follow-up of attenuated plaques in patients with acute myocardial infarction: an intravascular ultrasound substudy of the HORIZONS-AMI trial. <i>Circulation: Cardiovascular Interventions</i> , <b>2012</b> , 5, 185-92	6	16
174	What is the optimal antithrombotic strategy in primary percutaneous coronary intervention?. <i>Current Opinion in Cardiology</i> , <b>2012</b> , 27, 361-7	2.1	1
173	Impact of in-hospital major bleeding on outcomes in acute coronary syndromes. <i>Current Opinion in Cardiology</i> , <b>2012</b> , 27, 669-74	2.1	6
172	Letter by Mehran et al regarding article, "Bleeding academic research consortium consensus report: the food and drug administration perspective". <i>Circulation</i> , <b>2012</b> , 125, e460	16.7	3
171	Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2012</b> , 307, 1817-26	27.4	373
170	Bivalirudin versus heparin plus a glycoprotein IIb/IIIa inhibitor in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention after clopidogrel pretreatment: pooled analysis from the ACUITY and ISAR-REACT 4 trials. <i>Circulation: Cardiovascular Interventions</i> , <b>2012</b> , 5, 705-12	6	22
169	Prognostic significance of elevated baseline troponin in patients with acute coronary syndromes and chronic kidney disease treated with different antithrombotic regimens: a substudy from the ACUITY trial. <i>Circulation: Cardiovascular Interventions</i> , <b>2012</b> , 5, 157-65	6	12

168	Prognostic impact of a chronic total occlusion in a non-infarct-related artery in patients with ST-segment elevation myocardial infarction: 3-year results from the HORIZONS-AMI trial. <i>European Heart Journal</i> , <b>2012</b> , 33, 768-75	9.5	157
167	Clinical event committees in coronary stent trials: insights and recommendations based on experience in an unselected study population. <i>EuroIntervention</i> , <b>2012</b> , 8, 368-74	3.1	5
166	Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. <i>EuroIntervention</i> , <b>2012</b> , 8, 782-95	3.1	149
165	FAME and coronary stent investigations: is there a kink in the wire?. <i>Journal of the American College of Cardiology</i> , <b>2011</b> , 57, 115-6; author reply 116	15.1	2
164	Standardized endpoint definitions for Transcatheter Aortic Valve Implantation clinical trials: a consensus report from the Valve Academic Research Consortium. <i>Journal of the American College of Cardiology</i> , <b>2011</b> , 57, 253-69	15.1	662
163	Effect of switching antithrombin agents for primary angioplasty in acute myocardial infarction: the HORIZONS-SWITCH analysis. <i>Journal of the American College of Cardiology</i> , <b>2011</b> , 57, 2309-16	15.1	43
162	Prognostic impact of staged versus "one-time" multivessel percutaneous intervention in acute myocardial infarction: analysis from the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial. <i>Journal of the American College of Cardiology</i> , <b>2011</b> , 58, 704-11	15.1	192
161	Impact of the everolimus-eluting stent on stent thrombosis: a meta-analysis of 13 randomized trials. <i>Journal of the American College of Cardiology</i> , <b>2011</b> , 58, 1569-77	15.1	223
160	2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. <i>Journal of the American College of Cardiology</i> , <b>2011</b> , 58, 2550-2583	15.1	99
159	2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. <i>Journal of the American College of Cardiology</i> , <b>2011</b> , 58, e44-122	15.1	1703
158	Long-term outcome of percutaneous coronary intervention for chronic total occlusions. <i>JACC: Cardiovascular Interventions</i> , <b>2011</b> , 4, 952-61	5	213
157	Long-term impact of chronic kidney disease in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial. <i>Circulation</i> , <b>2011</b> , 124, 1011-8	5	89
156	Dual antiplatelet therapy duration and clinical outcomes following treatment with zotarolimus-eluting stents. <i>JACC: Cardiovascular Interventions</i> , <b>2011</b> , 4, 1119-28	5	28
155	Impact of intravascular ultrasound imaging on early and late clinical outcomes following percutaneous coronary intervention with drug-eluting stents. <i>JACC: Cardiovascular Interventions</i> , <b>2011</b> , 4, 974-81	5	90
154	A prospective natural-history study of coronary atherosclerosis. <i>New England Journal of Medicine</i> , <b>2011</b> , 364, 226-35	59.2	2044
153	A randomized, partially blinded, multicenter, active-controlled, dose-ranging study assessing the safety, efficacy, and pharmacodynamics of the REG1 anticoagulation system in patients with acute coronary syndromes: design and rationale of the RADAR Phase IIb trial. <i>American Heart Journal</i> , <b>2011</b> , 161, 301-6	4.9	29
152	Incidence and clinical consequences of acquired thrombocytopenia after antithrombotic therapies in patients with acute coronary syndromes: results from the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial. <i>American Heart Journal</i> , <b>2011</b> , 161, 298-306.e1	4.9	35
151	Impact of baseline thrombocytopenia on the early and late outcomes after ST-elevation myocardial infarction treated with primary angioplasty: analysis from the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial. <i>American Heart Journal</i> , <b>2011</b> , 161, 301-6	4.9	44

150	Changes in reference vessel diameter in ST-segment elevation myocardial infarction after primary percutaneous coronary intervention: implications for appropriate stent sizing. <i>American Heart Journal</i> , <b>2011</b> , 162, 173-7	4.9	7
149	Incidence and predictors of heart failure following percutaneous coronary intervention in ST-segment elevation myocardial infarction: the HORIZONS-AMI trial. <i>American Heart Journal</i> , <b>2011</b> , 162, 663-70	4.9	56
148	Relationship between angiographic dynamic and densitometric assessment of myocardial reperfusion and survival in patients with acute myocardial infarction treated with primary percutaneous coronary intervention: the harmonizing outcomes with revascularization and stents in AMI (HORIZONS-AMI) trial. <i>American Heart Journal</i> , <b>2011</b> , 162, 1044-51	4.9	19
147	Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. <i>Lancet, The</i> , <b>2011</b> , 377, 2193-204	4.0	358
146	Bivalirudin for patients with ST-elevation myocardial infarction. Authors Reply. <i>Lancet, The</i> , <b>2011</b> , 378, 1915-1916	4.0	1
145	Two-year safety and effectiveness of sirolimus-eluting stents (from a prospective registry). <i>American Journal of Cardiology</i> , <b>2011</b> , 107, 528-34	3	4
144	Long-term clinical outcomes of percutaneous coronary intervention for chronic total occlusions in patients with versus without diabetes mellitus. <i>American Journal of Cardiology</i> , <b>2011</b> , 108, 924-31	3	36
143	Predictors and implications of coronary infarct artery patency at initial angiography in patients with acute myocardial infarction (from the CADILLAC and HORIZONS-AMI Trials). <i>American Journal of Cardiology</i> , <b>2011</b> , 108, 918-23	3	39
142	Prognostic utility of left ventricular end-diastolic pressure in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. <i>American Journal of Cardiology</i> , <b>2011</b> , 108, 1068-74	3	35
141	Impact of smoking on outcomes of patients with ST-segment elevation myocardial infarction (from the HORIZONS-AMI Trial). <i>American Journal of Cardiology</i> , <b>2011</b> , 108, 1387-94	3	24
140	Comparison of direct stenting with conventional stent implantation in acute myocardial infarction. <i>American Journal of Cardiology</i> , <b>2011</b> , 108, 1697-703	3	33
139	Bleeding events are associated with an increase in markers of inflammation in acute coronary syndromes: an ACUITY trial substudy. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2011</b> , 31, 139-45	5.1	17
138	Predictive value of C-reactive protein on 30-day and 1-year mortality in acute coronary syndromes: an analysis from the ACUITY trial. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2011</b> , 31, 154-64	5.1	16
137	Impact of diabetes mellitus on the safety and effectiveness of bivalirudin in patients with acute myocardial infarction undergoing primary angioplasty: analysis from the HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) trial. <i>JACC: Cardiovascular Interventions</i> , <b>2011</b> , 4, 768-8	5	28
136	How serious a problem is bleeding in patients with acute coronary syndromes?. <i>Current Cardiology Reports</i> , <b>2011</b> , 13, 312-9	4.2	10
135	Incidence, prognostic impact, and influence of antithrombotic therapy on access and nonaccess site bleeding in percutaneous coronary intervention. <i>JACC: Cardiovascular Interventions</i> , <b>2011</b> , 4, 191-7	5	182
134	Autopsy validation study of the academic research consortium stent thrombosis definition. <i>JACC: Cardiovascular Interventions</i> , <b>2011</b> , 4, 554-9	5	30
133	Impact of bleeding on mortality after percutaneous coronary intervention results from a patient-level pooled analysis of the REPLACE-2 (randomized evaluation of PCI linking angiogram to reduced clinical events), ACUITY (acute catheterization and urgent intervention triage strategy), and HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trials. <i>JACC: Cardiovascular Interventions</i> , <b>2011</b> , 4, 54-64	5	274

132	Prognostic significance of coronary thrombus in patients undergoing percutaneous coronary intervention for acute coronary syndromes: a subanalysis of the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. <i>JACC: Cardiovascular Interventions</i> , <b>2011</b> , 4, 769-77	5	27
131	Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the Valve Academic Research Consortium. <i>European Heart Journal</i> , <b>2011</b> , 32, 205-17	9.5	510
130	Frequency and predictors of stent thrombosis after percutaneous coronary intervention in acute myocardial infarction. <i>Circulation</i> , <b>2011</b> , 123, 1745-56	16.7	193
129	Impact of chronic antiplatelet therapy before hospitalization on ischemic and bleeding events in invasively managed patients with acute coronary syndromes: the ACUITY trial. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , <b>2011</b> , 18, 121-8		8
128	Intravascular ultrasound findings of early stent thrombosis after primary percutaneous intervention in acute myocardial infarction: a Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) substudy. <i>Circulation: Cardiovascular Interventions</i> , <b>2011</b> , 4, 239-47	6	156
127	Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. <i>Circulation</i> , <b>2011</b> , 123, 2736-47	16.7	2467
126	2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. <i>Circulation</i> , <b>2011</b> , 124, 2574-609	16.7	389
125	Paclitaxel-eluting stents compared with bare metal stents in diabetic patients with acute myocardial infarction: the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial. <i>Circulation: Cardiovascular Interventions</i> , <b>2011</b> , 4, 130-8	6	8
124	Impact of leukocyte count on mortality and bleeding in patients with myocardial infarction undergoing primary percutaneous coronary interventions: analysis from the Harmonizing Outcome with Revascularization and Stent in Acute Myocardial Infarction trial. <i>Circulation</i> , <b>2011</b> , 123, 2829-37	16.7	47
123	Strut coverage and late malapposition with paclitaxel-eluting stents compared with bare metal stents in acute myocardial infarction: optical coherence tomography substudy of the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial. <i>Circulation</i> , <b>2011</b> , 123, 274-81	16.7	131
122	Predictors and implications of stent thrombosis in non-ST-segment elevation acute coronary syndromes: the ACUITY Trial. <i>Circulation: Cardiovascular Interventions</i> , <b>2011</b> , 4, 577-84	6	34
121	2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. <i>Circulation</i> , <b>2011</b> , 124, e574-651	16.7	1039
120	Drug-Eluting Stents: A Potential Preemptive Treatment Choice for Vulnerable Coronary Plaques <b>2011</b> , 661-669		
119	Serial intravascular ultrasound analysis of the impact of myocardial bridge on neointimal proliferation after coronary stenting in patients with acute myocardial infarction. <i>Journal of Interventional Cardiology</i> , <b>2010</b> , 23, 114-22	1.8	9
118	Clinical and angiographic predictors of short- and long-term ischemic events in acute coronary syndromes: results from the Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial. <i>Circulation: Cardiovascular Interventions</i> , <b>2010</b> , 3, 308-16	6	53
117	Impact of femoral vascular closure devices and antithrombotic therapy on access site bleeding in acute coronary syndromes: The Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial. <i>Circulation: Cardiovascular Interventions</i> , <b>2010</b> , 3, 57-62	6	79
116	Predictors of outcomes in medically treated patients with acute coronary syndromes after angiographic triage: an Acute Catheterization And Urgent Intervention Triage Strategy (ACUITY) substudy. <i>Circulation</i> , <b>2010</b> , 121, 853-62	16.7	28
115	Prognostic modeling of individual patient risk and mortality impact of ischemic and hemorrhagic complications: assessment from the Acute Catheterization and Urgent Intervention Triage Strategy trial. <i>Circulation</i> , <b>2010</b> , 121, 43-51	16.7	100

114	Clinical impact of enhanced inhibition of P2Y12-mediated platelet aggregation in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention. <i>Hospital Practice (1995)</i> , <b>2010</b> , 38, 38-43	2.2	2
113	Impact of delay to angioplasty in patients with acute coronary syndromes undergoing invasive management: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategy) trial. <i>Journal of the American College of Cardiology</i> , <b>2010</b> , 55, 1416-24	15.1	83
112	When is door-to-balloon time critical? Analysis from the HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) and CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) trials. <i>Journal of the American College of Cardiology</i> , <b>2010</b> , 56, 407-13	15.1	79
111	In-stent restenosis in the drug-eluting stent era. <i>Journal of the American College of Cardiology</i> , <b>2010</b> , 56, 1897-907	15.1	520
110	Selection criteria for drug-eluting versus bare-metal stents and the impact of routine angiographic follow-up: 2-year insights from the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial. <i>Journal of the American College of Cardiology</i> , <b>2010</b> , 56, 1597-604	15.1	69
109	A risk score to predict bleeding in patients with acute coronary syndromes. <i>Journal of the American College of Cardiology</i> , <b>2010</b> , 55, 2556-66	15.1	479
108	Evaluating the need for a practical risk score to predict major bleeding in acute coronary syndromes. <i>Interventional Cardiology</i> , <b>2010</b> , 2, 757-759	3	
107	Impact of anemia on clinical outcomes of patients with ST-segment elevation myocardial infarction in relation to gender and adjunctive antithrombotic therapy (from the HORIZONS-AMI trial). <i>American Journal of Cardiology</i> , <b>2010</b> , 105, 1385-94	3	63
106	Comparison of catheterization laboratory initiated abciximab and eptifibatide during percutaneous coronary intervention in acute coronary syndromes (an ACUITY substudy). <i>American Journal of Cardiology</i> , <b>2010</b> , 106, 180-6	3	2
105	Intravascular ultrasound findings of stent fractures in patients with Sirolimus- and Paclitaxel-eluting stents. <i>American Journal of Cardiology</i> , <b>2010</b> , 106, 952-7	3	8
104	Comparison of Bivalirudin versus Bivalirudin plus glycoprotein IIb/IIIa inhibitor versus heparin plus glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes having percutaneous intervention for narrowed saphenous vein aorto-coronary grafts (the ACUITY trial investigators). <i>American Journal of Cardiology</i> , <b>2010</b> , 106, 941-5	3	17
103	Impact of transfer for primary percutaneous coronary intervention on survival and clinical outcomes (from the HORIZONS-AMI Trial). <i>American Journal of Cardiology</i> , <b>2010</b> , 106, 1218-24	3	11
102	Predictors of reperfusion delay in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention from the HORIZONS-AMI trial. <i>American Journal of Cardiology</i> , <b>2010</b> , 106, 1527-33	3	39
101	Impact of bivalirudin therapy in high-risk patients with acute myocardial infarction: 1-year results from the HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) trial. <i>JACC: Cardiovascular Interventions</i> , <b>2010</b> , 3, 796-802	5	18
100	Surgical versus percutaneous revascularization for multivessel disease in patients with acute coronary syndromes: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. <i>JACC: Cardiovascular Interventions</i> , <b>2010</b> , 3, 1059-67	5	47
99	Myocardial infarction adjudication in contemporary all-comer stent trials: balancing sensitivity and specificity. Addendum to the historical MI definitions used in stent studies. <i>EuroIntervention</i> , <b>2010</b> , 5, 871-4	3.1	224
98	Bleeding Complications in Patients Undergoing Percutaneous Coronary Intervention <b>2010</b> , 240-249		
97	Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial. <i>European Heart Journal</i> , <b>2009</b> , 30, 1457-66	9.5	260

96	Early stent thrombosis in patients with acute coronary syndromes treated with drug-eluting and bare metal stents: the Acute Catheterization and Urgent Intervention Triage Strategy trial. <i>Circulation</i> , <b>2009</b> , 119, 687-98	16.7	154
95	Sodium bicarbonate for the prevention of contrast induced-acute kidney injury: a systematic review and meta-analysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2009</b> , 4, 1584-92	6.9	118
94	Are drug-eluting stents safe in the long term?. <i>Cmaj</i> , <b>2009</b> , 180, 154-5	3.5	5
93	Volumetric intravascular ultrasound analysis of Paclitaxel-eluting and bare metal stents in acute myocardial infarction: the harmonizing outcomes with revascularization and stents in acute myocardial infarction intravascular ultrasound substudy. <i>Circulation</i> , <b>2009</b> , 120, 1875-82	16.7	44
92	Impact of gender and antithrombin strategy on early and late clinical outcomes in patients with non-ST-elevation acute coronary syndromes (from the ACUITY trial). <i>American Journal of Cardiology</i> , <b>2009</b> , 103, 1196-203	3	70
91	Real world safety and efficacy of the Janus Tacrolimus-Eluting stent: long-term clinical outcome and angiographic findings from the Tacrolimus-Eluting STent (TEST) registry. <i>Catheterization and Cardiovascular Interventions</i> , <b>2009</b> , 73, 243-8	2.7	18
90	Impact of chronic kidney disease on early (30-day) and late (1-year) outcomes of patients with acute coronary syndromes treated with alternative antithrombotic treatment strategies: an ACUITY (Acute Catheterization and Urgent Intervention Triage strategy) substudy. <i>JACC: Cardiovascular Intervention</i> , <b>2009</b> , 2, 748-57	5	55
89	Outcomes of patients with coronary artery perforation complicating percutaneous coronary intervention and correlations with the type of adjunctive antithrombotic therapy: pooled analysis from REPLACE-2, ACUITY, and HORIZONS-AMI trials. <i>Journal of Interventional Cardiology</i> , <b>2009</b> , 22, 453-9	1.8	36
88	First-in-man 1-year clinical outcomes of the Catania Coronary Stent System with Nanothin Polyzene-F in de novo native coronary artery lesions: the ATLANTA (Assessment of The LATEST Non-Thrombogenic Angioplasty stent) trial. <i>JACC: Cardiovascular Interventions</i> , <b>2009</b> , 2, 197-204	5	27
87	Prognostic impact of blood transfusion after primary angioplasty for acute myocardial infarction: analysis from the CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) Trial. <i>JACC: Cardiovascular Interventions</i> , <b>2009</b> , 2, 624-32	5	55
86	Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies. <i>Circulation</i> , <b>2009</b> , 119, 3198-206	16.7	647
85	Standardized reporting of bleeding complications for clinical investigations in acute coronary syndromes: a proposal from the academic bleeding consensus (ABC) multidisciplinary working group. <i>American Heart Journal</i> , <b>2009</b> , 158, 881-886.e1	4.9	27
84	9-month clinical, angiographic, and intravascular ultrasound results of a prospective evaluation of the Axxess self-expanding biolimus A9-eluting stent in coronary bifurcation lesions: the DIVERGE (Drug-Eluting Stent Intervention for Treating Side Branches Effectively) study. <i>Journal of the American College of Cardiology</i> , <b>2009</b> , 53, 1031-9	15.1	88
83	Outcomes following pre-operative clopidogrel administration in patients with acute coronary syndromes undergoing coronary artery bypass surgery: the ACUITY (Acute Catheterization and Urgent Intervention Triage strategy) trial. <i>Journal of the American College of Cardiology</i> , <b>2009</b> , 53, 1965-72	15.1	114
82	5-year clinical outcomes after sirolimus-eluting stent implantation insights from a patient-level pooled analysis of 4 randomized trials comparing sirolimus-eluting stents with bare-metal stents. <i>Journal of the American College of Cardiology</i> , <b>2009</b> , 54, 894-902	15.1	135
81	Role of clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty: results from the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial. <i>Journal of the American College of Cardiology</i> , <b>2009</b> , 54, 1120-11	15.1	130
80	Gastrointestinal bleeding in patients with acute coronary syndromes: incidence, predictors, and clinical implications: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. <i>Journal of the American College of Cardiology</i> , <b>2009</b> , 54, 1293-302	15.1	133
79	Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction. <i>New England Journal of Medicine</i> , <b>2009</b> , 360, 1946-59	59.2	577

78	Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. <i>Lancet, The</i> , <b>2009</b> , 374, 1149-59	40	308
77	Prognostic significance of periprocedural versus spontaneously occurring myocardial infarction after percutaneous coronary intervention in patients with acute coronary syndromes: an analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. <i>Journal of the American College of Cardiology</i> , <b>2009</b> , 54, 477-86	15.1	138
76	Choice of arterial access site and outcomes in patients with acute coronary syndromes managed with an early invasive strategy: the ACUITY trial. <i>EuroIntervention</i> , <b>2009</b> , 5, 115-20	3.1	92
75	Short- and long-term outcomes after stent-assisted percutaneous treatment of saphenous vein grafts in the drug-eluting stent era. <i>American Journal of Cardiology</i> , <b>2008</b> , 101, 63-8	3	47
74	Effectiveness of drug-eluting stent implantation for patients with unprotected left main coronary artery stenosis. <i>American Journal of Cardiology</i> , <b>2008</b> , 101, 801-6	3	55
73	Angiographic patterns of drug-eluting stent restenosis and one-year outcomes after treatment with repeated percutaneous coronary intervention. <i>American Journal of Cardiology</i> , <b>2008</b> , 102, 311-5	3	50
72	Drug-eluting stents in the real world: how intravascular ultrasound can improve clinical outcome. <i>American Journal of Cardiology</i> , <b>2008</b> , 102, 24J-8J	3	20
71	Paclitaxel-eluting coronary stents in patients with diabetes mellitus: pooled analysis from 5 randomized trials. <i>Journal of the American College of Cardiology</i> , <b>2008</b> , 51, 708-15	15.1	96
70	Safety and efficacy of bivalirudin monotherapy in patients with diabetes mellitus and acute coronary syndromes: a report from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. <i>Journal of the American College of Cardiology</i> , <b>2008</b> , 51, 1645-52	15.1	56
69	Safety and efficacy of switching from either unfractionated heparin or enoxaparin to bivalirudin in patients with non-ST-segment elevation acute coronary syndromes managed with an invasive strategy: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategy) trial. <i>Journal of the American College of Cardiology</i> , <b>2008</b> , 51, 1731-41	15.1	64
68	A novel bioresorbable polymer paclitaxel-eluting stent for the treatment of single and multivessel coronary disease: primary results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II study. <i>Journal of the American College of Cardiology</i> , <b>2008</b> , 51, 1543-52	15.1	97
67	Safety and efficacy of bivalirudin with and without glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention 1-year results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategy) trial. <i>Journal of the American College of Cardiology</i> , <b>2008</b> , 52, 887-94	15.1	60
66	Economic evaluation of bivalirudin with or without glycoprotein IIb/IIIa inhibition versus heparin with routine glycoprotein IIb/IIIa inhibition for early invasive management of acute coronary syndromes. <i>Journal of the American College of Cardiology</i> , <b>2008</b> , 52, 1758-68	15.1	64
65	The Harmonizing Outcomes with RevascularizatiON and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial: study design and rationale. <i>American Heart Journal</i> , <b>2008</b> , 156, 44-56	4.9	144
64	Bivalirudin during primary PCI in acute myocardial infarction. <i>New England Journal of Medicine</i> , <b>2008</b> , 358, 2218-30	59.2	1457
63	Influence of timing of clopidogrel treatment on the efficacy and safety of bivalirudin in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention: an analysis of the ACUITY (Acute Catheterization and Urgent Intervention Triage strategy) Trial. <i>JACC: Cardiovascular Interventions</i> , <b>2008</b> , 1, 639-48	5	49
62	Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. <i>New England Journal of Medicine</i> , <b>2007</b> , 356, 998-1008	59.2	1555
61	Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial. <i>Journal of the American College of Cardiology</i> , <b>2007</b> , 49, 1362-8	15.1	665



60	Gender-specific outcomes after sirolimus-eluting stent implantation. <i>Journal of the American College of Cardiology</i> , <b>2007</b> , 50, 2111-6	15.1	90
59	Nonrandomized comparison of coronary stenting under intravascular ultrasound guidance of direct stenting without predilation versus conventional predilation with a semi-compliant balloon versus predilation with a new scoring balloon. <i>American Journal of Cardiology</i> , <b>2007</b> , 100, 812-7	3	65
58	Off-label use of drug-eluting stents: assessing the risk. <i>Nature Clinical Practice Cardiovascular Medicine</i> , <b>2007</b> , 4, 594-5		2
57	Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2007</b> , 297, 591-602	27.4	226
56	Impact of multivessel disease on reperfusion success and clinical outcomes in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction. <i>European Heart Journal</i> , <b>2007</b> , 28, 1709-16	9.5	311
55	Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2007</b> , 298, 2497-506	27.4	185
54	Assessing intermediate left main coronary lesions using intravascular ultrasound. <i>American Heart Journal</i> , <b>2007</b> , 154, 983-8	4.9	73
53	Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. <i>Lancet, The</i> , <b>2007</b> , 369, 907-19	40	322
52	Development and validation of a prognostic risk score for major bleeding in patients undergoing percutaneous coronary intervention via the femoral approach. <i>European Heart Journal</i> , <b>2007</b> , 28, 1936-43	9.5	192
51	Clinical end points in coronary stent trials: a case for standardized definitions. <i>Circulation</i> , <b>2007</b> , 115, 2344-51	16.7	4380
50	Bivalirudin for patients with acute coronary syndromes. <i>New England Journal of Medicine</i> , <b>2006</b> , 355, 2203-16	59.2	1167
49	Impact of routine angiographic follow-up on the clinical benefits of paclitaxel-eluting stents: results from the TAXUS-IV trial. <i>Journal of the American College of Cardiology</i> , <b>2006</b> , 48, 32-6	15.1	123
48	Percutaneous recanalization of chronically occluded coronary arteries: a consensus document: part II. <i>Circulation</i> , <b>2005</b> , 112, 2530-7	16.7	237
47	Impact of moderate renal insufficiency on restenosis and adverse clinical events after paclitaxel-eluting and bare metal stent implantation: results from the TAXUS-IV Trial. <i>American Heart Journal</i> , <b>2005</b> , 150, 1163-70	4.9	77
46	Outcomes of paclitaxel-eluting stent implantation in patients with stenosis of the left anterior descending coronary artery. <i>Journal of the American College of Cardiology</i> , <b>2005</b> , 45, 1186-92	15.1	35
45	Intravascular ultrasound assessment of lesions with target vessel failure after sirolimus-eluting stent implantation. <i>American Journal of Cardiology</i> , <b>2005</b> , 95, 498-502	3	81
44	Vasa vasorum imaging: a new window to the clinical detection of vulnerable atherosclerotic plaques. <i>Current Atherosclerosis Reports</i> , <b>2005</b> , 7, 164-9	6	93
43	Outcome in elderly patients undergoing primary coronary intervention for acute myocardial infarction: results from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. <i>Circulation</i> , <b>2004</b> , 110, 1598-604	16.7	107

42	Contribution of stent underexpansion to recurrence after sirolimus-eluting stent implantation for in-stent restenosis. <i>Circulation</i> , <b>2004</b> , 109, 1085-8	16.7	221
41	Gamma radiation for in-stent restenosis: effect of lesion length on angiographic and clinical outcomes. <i>Catheterization and Cardiovascular Interventions</i> , <b>2004</b> , 61, 354-9	2.7	2
40	Favorable effect of gamma-radiation for in-stent restenosis: effect of diabetes on angiographic and clinical outcomes. <i>Catheterization and Cardiovascular Interventions</i> , <b>2004</b> , 62, 303-7	2.7	2
39	Successful use of the frontrunner catheter in the treatment of in-stent coronary chronic total occlusions. <i>Catheterization and Cardiovascular Interventions</i> , <b>2004</b> , 63, 462-8	2.7	25
38	Randomized trial of Rotational Atherectomy Versus Balloon Angioplasty for Diffuse In-stent Restenosis (ROSTER). <i>American Heart Journal</i> , <b>2004</b> , 147, 16-22	4.9	79
37	Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale. <i>American Heart Journal</i> , <b>2004</b> , 148, 764-75	4.9	210
36	Vascular complications associated with arteriotomy closure devices in patients undergoing percutaneous coronary proceduresA meta-analysis. <i>Journal of the American College of Cardiology</i> , <b>2004</b> , 44, 1200-1209	15.1	342
35	New approaches to preventing restenosis. <i>BMJ, The</i> , <b>2003</b> , 327, 274-9	5.9	62
34	Usefulness of the angiographic pattern of in-stent restenosis in predicting the success of gamma vascular brachytherapy. <i>American Journal of Cardiology</i> , <b>2003</b> , 92, 1214-7	3	3
33	Comparison of the angiographic outcomes after beta versus gamma vascular brachytherapy for treatment of in-stent restenosis. <i>American Journal of Cardiology</i> , <b>2003</b> , 92, 1409-13	3	22
32	Usefulness of beta radiation for de novo and in-stent restenotic lesions in saphenous vein grafts. <i>American Journal of Cardiology</i> , <b>2003</b> , 92, 312-4	3	13
31	Effect of percutaneous coronary interventions for in-stent restenosis in degenerated saphenous vein grafts without distal embolic protection. <i>Journal of the American College of Cardiology</i> , <b>2003</b> , 41, 749-52	15.1	22
30	Intravascular brachytherapy for native coronary ostial in-stent restenotic lesions. <i>Journal of the American College of Cardiology</i> , <b>2003</b> , 41, 1725-31	15.1	8
29	From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. <i>Circulation</i> , <b>2003</b> , 108, 1664-72	16.7	1985
28	From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. <i>Circulation</i> , <b>2003</b> , 108, 1772-8	16.7	886
27	Coronary artery stenting. <i>Catheterization and Cardiovascular Interventions</i> , <b>2002</b> , 56, 83-102	2.7	11
26	Quantitative angiographic methods for appropriate end-point analysis, edge-effect evaluation, and prediction of recurrent restenosis after coronary brachytherapy with gamma irradiation. <i>Journal of the American College of Cardiology</i> , <b>2002</b> , 39, 274-80	15.1	102
25	Clinical outcomes of compromised side branch (stent jail) after coronary stenting with the NIR stent. <i>Catheterization and Cardiovascular Interventions</i> , <b>2001</b> , 54, 295-300	2.7	21

24	Differential impact on survival of electrocardiographic Q-wave versus enzymatic myocardial infarction after percutaneous intervention: a device-specific analysis of 7147 patients. <i>Circulation</i> , <b>2001</b> , 104, 642-7	16.7	174
23	Serial intravascular ultrasound assessment of the efficacy of intracoronary gamma-radiation therapy for preventing recurrence in very long, diffuse, in-stent restenosis lesions. <i>Circulation</i> , <b>2001</b> , 104, 856-9	16.7	37
22	Intravascular ultrasound-guided renal artery stenting. <i>Journal of Endovascular Therapy</i> , <b>2001</b> , 8, 238-47	2.5	26
21	Treatment of focal in-stent restenosis with balloon angioplasty alone versus stenting: Short- and long-term results. <i>American Heart Journal</i> , <b>2001</b> , 141, 610-4	4.9	39
20	Intravascular Ultrasound-Guided Renal Artery Stenting. <i>Journal of Endovascular Therapy</i> , <b>2001</b> , 8, 238-247	2.5	20
19	Prognostic value of recurrent episodes of creatine kinase-MB elevation following repeated catheter-based coronary interventions. <i>Catheterization and Cardiovascular Interventions</i> , <b>2000</b> , 51, 131-7	2.7	6
18	Intracoronary brachytherapy not associated with changes in major side branches. <i>Catheterization and Cardiovascular Interventions</i> , <b>2000</b> , 51, 154-8	2.7	3
17	Safety of intracoronary gamma-radiation on uninjured reference segments during the first 6 months after treatment of in-stent restenosis: a serial intravascular ultrasound study. <i>Circulation</i> , <b>2000</b> , 101, 2227-30	16.7	20
16	Intracoronary beta-radiation therapy inhibits recurrence of in-stent restenosis. <i>Circulation</i> , <b>2000</b> , 101, 1895-8	16.7	278
15	Treatment of in-stent restenosis with excimer laser coronary angioplasty versus rotational atherectomy: comparative mechanisms and results. <i>Circulation</i> , <b>2000</b> , 101, 2484-9	16.7	119
14	Atherosclerotic plaque burden and CK-MB enzyme elevation after coronary interventions : intravascular ultrasound study of 2256 patients. <i>Circulation</i> , <b>2000</b> , 101, 604-10	16.7	221
13	Late total occlusion after intracoronary brachytherapy for patients with in-stent restenosis. <i>Journal of the American College of Cardiology</i> , <b>2000</b> , 36, 65-8	15.1	195
12	The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency. <i>Journal of the American College of Cardiology</i> , <b>2000</b> , 36, 1542-8	15.1	572
11	Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. <i>Circulation</i> , <b>1999</b> , 100, 1872-8	16.7	1016
10	Percutaneous transcatheter management of giant coronary aneurysms. <i>Circulation</i> , <b>1999</b> , 100, E8-E11	16.7	13
9	Creatine kinase-MB enzyme elevation following successful saphenous vein graft intervention is associated with late mortality. <i>Circulation</i> , <b>1999</b> , 100, 2400-5	16.7	200
8	Tissue proliferation within and surrounding Palmaz-Schatz stents is dependent on the aggressiveness of stent implantation technique. <i>American Journal of Cardiology</i> , <b>1999</b> , 83, 1170-4	3	104
7	One-year follow-up after intravascular ultrasound assessment of moderate left main coronary artery disease in patients with ambiguous angiograms. <i>Journal of the American College of Cardiology</i> , <b>1999</b> , 34, 707-15	15.1	147

6	The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation. <i>Journal of the American College of Cardiology</i> , <b>1998</b> , 32, 584-9	15.1	363
5	Validation of the in vivo intravascular ultrasound measurement of in-stent neointimal hyperplasia volumes. <i>Journal of the American College of Cardiology</i> , <b>1998</b> , 32, 794-9	15.1	55
4	Early lumen loss after treatment of in-stent restenosis: an intravascular ultrasound study. <i>Circulation</i> , <b>1998</b> , 98, 200-3	16.7	69
3	Procedural results and late clinical outcomes after placement of three or more stents in single coronary lesions. <i>Circulation</i> , <b>1998</b> , 97, 1355-61	16.7	56
2	In-Stent Restenosis in the DES Era442-463		
1	Antithrombotic Therapy in NonST-Segment Elevation Acute Coronary Syndromes213-235		